Mammalian induced pluripotent stem cells

A novel combination of reprogramming factors effectively transforms bovine somatic cells into iPSCs, addressing the challenge of resistant cells and ensuring pluripotency for cultured meat production.

WO2026234668A1PCT designated stage Publication Date: 2026-11-12YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2026/050376
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing methods struggle to efficiently reprogram bovine somatic cells into induced pluripotent stem cells (iPSCs) for use in cultured meat production, as some cells are resistant to reprogramming by known combinations of markers.

Method used

A novel combination of five or more reprogramming factors, including OCT4, chimeric SOX2, a factor of the KLF family, and at least two factors from the SALL and PRDM families, along with agents downregulating transcription factors like p53 and AP-1, is introduced into bovine somatic cells to achieve iPSC production.

Benefits of technology

The method efficiently produces iPSCs that maintain pluripotency under conventional growth conditions, enabling their indefinite propagation and differentiation into various cell types, suitable for cultured meat production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000065_0001
    Figure IMGF000065_0001
  • Figure IMGF000065_0002
    Figure IMGF000065_0002
  • Figure IMGF000065_0003
    Figure IMGF000065_0003
Patent Text Reader

Abstract

The present invention provides methods of producing mammalian induced pluripotent stem cells (iPSCs) comprising introducing a novel combination of reprogramming factors into mammalian somatic cells. Also disclosed herein are a plurality of mammalian iPSCs and somatic cells, such as bovine cells, produced by the methods of the present invention and their use in producing cultured food product, particularly cultured meat.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] MAMMALIAN INDUCED PLURIPOTENT STEM CELLS FILED OF THE INVENTION

[0002] The present invention provides compositions and methods for obtaining mammalian induced pluripotent stem cells (iPSCs), particularly to a combination of reprogramming factors inducing reprogramming of mammalian differentiated somatic cells to derive iPSCs, and use of the iPSCs in food industry, cosmetics and medicine. Specifically, prepared bovine iPSCs may be used in production of cell-based meat products.

[0003] BACKGROUND OF THE INVENTION

[0004] Pluripotent stem cells are characterized by the ability of self-renewal and differentiation into a diverse range of cell types.

[0005] Reprogramming factors are crucial components in the field of cellular reprogramming, where somatic cells are transformed into induced pluripotent stem cells (iPSCs). These factors play a pivotal role in resetting the epigenetic landscape of cells, allowing them to regain pluripotency and the potential to differentiate into various cell types. Through the introduction of these reprogramming factors into somatic cells, the cellular identity of the cells is going through "reset", effectively turning back the developmental clock.

[0006] Bovine iPSCs represent a promising avenue of research in the field of cellular agriculture and optionally in veterinary medicine. These specialized cells, derived from bovine somatic cells, possess the unique ability to differentiate into various cell types found in the bovine body.

[0007] Reprogramming cells into iPSCs was first described by Takahashi and Yamanaka in 2006 (Takahashi and Yamanaka, Cell 2006, 126: 663-76), followed by a number of patents and patent applications of these authors. For Example, European Patent No.

[0008] 3418297 discloses nuclear reprogramming factor for a somatic cell, which comprises a gene product of each of the following three kinds of genes: an Oct family gene, a Klf family gene, and a Myc family gene, as a means for inducing reprogramming of a differentiated cell to conveniently and highly reproducibly establish an inducedpluripotent stem cell having pluripotency and growth ability similar to those of embryonic stem (ES) cells without using embryo or ES cell.

[0009] Since then, a large number of publications described reprogramming somatic cells to iPSCs, from various cell types in multiple species.

[0010] For example, MacCarthy et al. (Cell Stem Cell 2024, 31(1): 127-147) describes the use of the reprogramming factors using episomal S 0X2-17-P2A-KLF4 combined with OCT4-shTP53 and L-MYC-F2A-LIN28 vectors (0S*KML) to generate bovine iPSCs from bovine embryonic fibroblasts using bFGF-based (StemFlex) media supplemented with a Wnt inhibitor (XAV939).

[0011] Cultured or cultivated meat represents a groundbreaking innovation in the field of food technology, offering a sustainable and ethical alternative to traditional animal farming. Unlike conventional meat production, which involves raising and slaughtering animals, cultured meat is produced by cultivating animal cells in a laboratory setting. These cells are typically harvested from a small biopsy of live animals and then grown in a nutrient-rich medium, where they multiply and develop into muscle tissue. The result is a meat food product that is similar to conventional meat but produced without the need for animal slaughter. Cultured meat has the potential to address many of the environmental, ethical, and public health concerns associated with traditional meat production, including reducing greenhouse gas emissions, minimizing animal suffering, and mitigating the risk of zoonotic diseases. As research and development efforts continue, cultured meat holds promise as a sustainable and humane protein source for feeding a growing global population.

[0012] It is well known that some somatic cell cannot be reprogrammed by methods previously described. There is an unmet need to efficiently produce iPSCs from such cells resistant to reprogramming, specifically bovine somatic cells, that may be used to produce cultured food product, specifically cultured meat.

[0013] SUMMARY OF THE INVENTION

[0014] The present invention answers the long felt need for methods of reprogramming differentiated somatic cells to derive iPSCs that showed resistance to reprogramming by known methods and known combinations of markers. Examples of such cells are bovinesomatic cells. This is useful in the growing industry of cell grown meat products. The compositions and methods provided by the present invention are designed to be applicable in the food industry, cosmetics and medicine in terms of mass production, cost, and safety.

[0015] The present invention is based in part on the unexpected discovery of a minimal combination of reprogramming factors, the insertion of which into bovine embryonic stem cells differentiated to collagen-producing stromal cells (also designated herein “fibroblast-like cells”) and / or into bovine dermal fibroblasts resulted in reprogramming of the somatic cells to iPSCs exhibiting the appropriate morphology and expressing key proteins indicative of pluripotency. Furthermore, the generated iPSCs displayed the capacity for growth and propagation under conventional bovine iPSC culture conditions.

[0016] According to certain aspects, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs) comprising introducing into one or more mammalian somatic cells a combination of five or more reprogramming factors or at least one exogenous polynucleotide encoding the five or more reprogramming factors, wherein the reprogramming factors comprise OCT4, chimeric SOX2, a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family, thereby producing one or more bovine iPSCs. In some examples, the method comprising introducing into one or more mammalian somatic cells at least one exogenous polynucleotide encoding five or more reprogramming factors, t In some examples, the method comprising introducing into one or more mammalian somatic cells five or more reprogramming factor proteins.

[0017] According to certain embodiments, the reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, and a factor of the SALL family.

[0018] According to certain embodiments, the reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, and a factor of the PRDM family.

[0019] According to certain embodiments, the reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, a factor of the SALL family, and a factor of the PRDM family.

[0020] According to certain exemplary embodiments, the reprogramming factors comprise0CT4, a chimeric S0X2, a factor of the KLF family, NANOG, a factor of the SALL family and a factor of the PRDM family.

[0021] According to certain embodiments, the chimeric S0X2 comprises SOX2 or a truncated SOX2 and from 1 to 20 copies of an exogenous transactivation domain. According to certain embodiments, the transactivation domain is derived from a protein selected from the group consisting VP16, VP48, VP64 and SOX17. According to certain embodiments, the chimeric SOX2 comprises from 1 to 20 repeats of VP16 activation domains. According to certain embodiments, the chimeric SOX2 comprises 10 repeats of VP16 activation domains (VP160). According to certain embodiments, the method further comprises introducing at least one additional reprograming factors selected from LIN28A and MYCL or at least one exogenous polynucleotide encoding the at least one additional reprograming factor. According to further embodiments, method further comprises introducing at least one agent downregulating a transcription factor selected from the group consisting of p53 and AP-1 or a part thereof or the at least one exogenous polynucleotide encoding the at least one agent. According to some examples, an agent downregulating p53 is selected from p53DD, shp53 and GSE56 and the agent downregulating AP-1 or a part thereof is selected from JDP2, shFOS and shJUN.

[0022] According to certain embodiments, the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, and an agent downregulating p53.

[0023] According to certain embodiments, the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, a factor of the PRDM family, and agents downregulating p53 and AP-1.

[0024] According to certain embodiments, the method comprises introducing acombination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, a factor of the PRDM family, agents downregulating p53 and AP-1, and a factor of the LIN28 family.

[0025] According to certain embodiments, the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, a factor of the PRDM family, agents downregulating p53 and AP-1 or a part thereof, a factor of the LIN28 family, and MYCL According to certain embodiments, the factor of the KLF family is selected from the group consisting of KLF4, KLF5, KLF2, KLF6 and KLF17.

[0026] According to certain embodiments, the factor of the SALL family is selected from the group consisting of SALL4, SALL1, SALL2 and SALL3.

[0027] According to certain embodiments, the factor of the PRDM family is selected from the group consisting of PRDM 14 and PRDML

[0028] According to certain embodiments, the factor of the LIN28 family is selected from LIN28A and LIN28B.

[0029] According to certain embodiments, the agent downregulating p53 is selected from the group consisting of p53 dominant-negative mutant of p53 (p53DD), MDM2, HPV E6 Protein, p53-silencing molecule selected from the group consisting of p53 siRNA, shp53, CRISPR / Cas9 mediating p53 silencing, and the like.

[0030] According to certain embodiments, the agent downregulating AP-1 or a part thereof is selected from the group consisting of JDP2, BATF, c-FOS / c-JUN siRNA, sh c-FOS / c-JUN, CRISPR / Cas9 mediating c-FOS / c-JUN silencing, c-FOS / c-JUN-silencing molecule. Each possibility represents a separate embodiment of the present invention. According to certain embodiments, the agent is JDP2.According to certain exemplary embodiments, the reprogramming factors compriseOCT4, a chimeric SOX2 selected from the group consisting of SOX2-VP160 and SOX2-17, KLF4, NANOG, and SALL4.

[0031] According to certain exemplary embodiments, the reprogramming factors compriseOCT4, a chimeric SOX2 selected from the group consisting of SOX2-VP160 and SOX2-17, KLF4, NANOG, SALL4 and PRDM14.

[0032] According to some embodiments, the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, SALL4, and p53DD.

[0033] According to some embodiments, the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, SALL4, p53DD and JDP2.

[0034] According to some embodiments, the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factors or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, SALL4, p53DD, JDP2 and PRDM14.

[0035] According to some embodiments, the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, LIN28A, MYCL, NANOG, SALL4 and p53DD.

[0036] According to some embodiments, the method comprises introducing a combinationcomprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, LIN28A, MYCL, SALL4, p53DD and JDP2.

[0037] According to some embodiments, the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, SALL4, LIN28A, MYCL, p53DD, and PRDM14, and optionally JDP2.

[0038] According to some examples, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs) comprising introducing into one or more mammalian somatic cells a combination comprising five or more reprogramming factors and one or more agents downregulating a transcription factor selected from the group consisting of p53, AP-1 or a part thereof, and a combination thereof, or at least one exogenous polynucleotide encoding the reprogramming factors and the one or more agents downregulating a transcription factor, wherein the reprogramming factors comprise OCT4, chimeric SOX2, a factor of the KLF family, a factor of LIN28 family and a factor of MYC family, thereby producing one or more bovine iPSCs. According to some examples, the method is characterized by at least one of:

[0039] (i) an agent downregulating p53 is selected from p53DD, shp53 and GSE56;

[0040] (ii) an agent downregulating AP-1 or a part thereof is selected from JDP2, shFOS and shJUN;

[0041] (iii) the chimeric SOX2 is selected from the group consisting of S 0X2- 17 and S0X2-VP160;

[0042] (iv) the factor of the KLF family is selected from the group consisting of KLF4, KLF5, KLF2, KLF6 and KLF17;

[0043] (v) the factor of the SALL family is selected from the group consisting of SALL4, SALL1, SALL2 and SALL3;(vi) the factor of LIN28 family is selected from LIN28A and LYN28B; and

[0044] (vii) the factor of MYC family is selected from MYC-L, MYC-N, and c-MYC.

[0045] The present invention shows that the hitherto unknown combination of reprogramming factors provides for an efficient production of iPSC, which maintain their pluripotency when grown and propagated under conventional growth conditions for at least 20 passages.

[0046] According to some embodiments, the method comprises introducing into the one or more mammalian somatic cells at least one exogenous polynucleotide encoding the reprogramming factors and optionally an agent downregulating a transcription factor.

[0047] According to certain embodiments, the method comprises introducing into the one or more mammalian somatic cells a plurality of polynucleotides, wherein each of the plurality of polynucleotides encodes the one or more reprogramming factors and / or the agent(s).

[0048] According to certain embodiments, wherein each of the plurality of polynucleotides encodes a single reprogramming factor or the agent.

[0049] According to certain embodiments, the at least one exogenous polynucleotide is a gene-delivery and / or expression vector comprising a nucleic acid sequence encoding the at least one or more reprogramming factor. According to some embodiments, the genedelivery and / or expression vector is selected from the group consisting of an integrating vector and a non-integrating vector.

[0050] According to certain embodiments, the non-integrating vector is selected from the group consisting of, but not limited to, episomal vector, Sendai virus (SeV) vector, and adenovirus vector. Each possibility represents a separate embodiment of the present invention.

[0051] According to certain embodiments, the integrating vector is selected from the group consisting of, but not limited to, lentiviral vector and retroviral vector. Each possibility represents a separate embodiment of the present invention.

[0052] According to certain embodiment, the at least one exogenous polynucleotide comprises a mRNA encoding the one or more reprogramming factor.

[0053] The inventors of the present invention have discovered that the origin of thereprogramming factor is of less significance in producing the mammalian iPSC, as long as the combination of five or more factors is used.

[0054] According to certain embodiments, the origin of the reprogramming factor is mammalian. According to some embodiments, the mammalian reprogramming factor is an ungulate factor, particularly bovine factor. According to some additional or alternative embodiments, the mammalian reprogramming factor is a human factor. According to yet further additional or alternative embodiments, the mammalian reprograming factor is a murine factor. According to yet further additional or alternative embodiments, the mammalian reprograming factor is a combination of bovine, human and murine factor.

[0055] According to some examples, the mammalian somatic cells are selected from peripheral blood cells, mesenchymal stem cells, fibroblasts, keratinocytes, urine-derived and epithelial cells.

[0056] According to some examples, the mammalian somatic cells are bovine somatic cells.

[0057] The one or more bovine somatic cells that may be used according to the teachings of the invention can be fresh cells or cells obtained from a frozen stock. The cells may be somatic cells or non-pluripotent progenitor cells directly derived from a bovine tissue or differentiated from embryonic stem cells derived from a bovine blastocyte.

[0058] According to certain embodiments, the bovine somatic cell is selected from the group consisting of bovine fibroblasts and bovine fibroblasts-like cells.

[0059] According to certain embodiment, bovine fibroblast cells are bovine dermal fibroblast cells.

[0060] According to certain embodiments, the bovine fibroblast-like cells are mesenchymal (stromal) cells differentiated from embryonic stem cells (ESCs) obtained from cattle.

[0061] According to some embodiments, the method further comprising growing the resulted iPSC cells.

[0062] The present invention further provides a plurality of mammalian iPSCs produced by the methods of the present invention. According to some examples, the mammalian iPSCs produced by the methods of the present invention are bovine iPSCs.According to some examples, the present resulting iPSCs, such as bovine iPSCs, can propagate indefinitely in culture.

[0063] According to certain embodiments, the plurality of iPSCs express at least one of the endogenous factors OCT4, SOX2, LIN28A, SALL4, UTF1, and ZFP42.

[0064] According to some embodiments, the resulting mammalian iPSC are for use in food industry, cosmetics or medicine.

[0065] According to certain embodiments, the said iPSCs are bovine iPSCs. According to some embodiments, the plurality of bovine iPSCs is used in producing cultured food product. According to certain embodiments, the cultured food product is cultured meat.

[0066] According to certain embodiments, the present invention further provides a method for producing one or more bovine somatic cells, comprising the steps of:

[0067] a. producing one or more mammalian iPSCs according to the methods of the invention; and

[0068] b. culturing the produced bovine iPSCs under conditions enabling propagation and differentiation of the produced iPSC, thereby producing one or more mammalian somatic cells. According to certain embodiments, the said cells are bovine cells.

[0069] According to certain embodiments, culturing the iPSCs produced by the methods of the invention comprises culturing said iPSC under 2D or 3D culture conditions.

[0070] According to certain embodiments, the produced one or more bovine somatic cells is selected from the group consisting of stromal cells, skeletal muscle cells, adipocytes, endothelial cell, and any combination thereof. Each possibility represents a separate embodiment of the present invention.

[0071] The present invention further provides bovine somatic cell produced by the methods of the invention. According to certain embodiments, the produced bovine somatic cell is for use in producing cultured food product. According to certain embodiments, the cultured food product is cultured meat.

[0072] According to additional certain aspects, the present invention provides a chimeric SOX2-VP160 polypeptide comprising an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO:1 for use in reprogramming bovine-derived somatic cell to produce bovine induced pluripotent stem cell (iPSC).

[0073] According to yet further aspects, the present invention provides an induced pluripotent stem cell (iPSC), which is obtainable by introducing into a mammalian somatic cell at least one exogenous polynucleotide encoding five or more reprogramming factors or by introducing into a mammalian somatic cell a combination of five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, chimeric SOX2, and a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family.

[0074] According to further certain aspects, the present invention provides a combination comprising five or more reprogramming factors or at least one polynucleotide encoding same, wherein the combination comprises OCT4, chimeric SOX2, and a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family.

[0075] According to certain embodiments, the combination further comprises one or more reprograming factors selected from the group consisting of LIN28A, and MYCL. According to certain embodiments, the combination further comprises at least one agent downregulating a transcription factor selected from the group consisting of p53, AP-1 or a part thereof, and any combination thereof. The combination may comprise the factor proteins or at least one polynucleotide encoding same.

[0076] It is to be understood that any combination of each of the aspects and the embodiments disclosed herein is explicitly encompassed within the disclosure of the present invention.

[0077] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF THE DRAWINGS

[0078] Figs. 1A-1B are representative bright field images showing bovine dermal fibroblasts (BDFs) after electroporation using episomal vectors comprising the reprogramming factors hOCT4, hKLF4, hLIN28A, hMYCL and hSOX2 (Fig. 1A) or hSOX2-17 (Fig. IB).

[0079] Figs.2A-2B are representative bright field images showing an iPSC colony in BDFs (Fig.

[0080] 2A) and fibroblast-like cells (Fig. 2B) after electroporation using episomal vectors comprising the reprogramming factors hOCT4, hSOX2-17, hKLF4, hLIN28A, hMYCL bNANOG, hSALL4 and mPRDM14 (h- human, b- bovine, m- mice).

[0081] Figs. 3A-3B are representative bright field images showing iPSCs (3A) and fibroblastlike cells after electroporation (3B). Fig. 3A shows successful generation of bovine iPSC using episomal vectors comprising the reprogramming factors hOCT4, hSOX2-VP160, hKLF4, hLIN28A, hMYCL, bNANOG, hSALL4 and mPRDM14.

[0082] Fig. 3B shows unsuccessful generation of bovine iPSC using episomal vectors due to subtraction of hOCT4 (uper), hSOX2-VP160 (lower left ) or hKLF4 (lower right) from the reprogramming factors combination of Fig. 3A.

[0083] Figs. 4A-4F show a successful production of bovine iPSC from fibroblast-like cells after electroporation using episomal vectors comprising only 5 (five) reprogramming factors: hOCT4, hSOX2-17, hKLF4, bNANOG and hSALL4. Fig. 4A is a representative bright field image showing an iPSC colony generated from electroporation with the 5 reprogramming factors. Fig. 4B shows an immunofluorescence image of the expression of the endogenous iPSC markers - bOCT4 and bSOX2, in the iPSC colony of Fig. 4A. Figs.4C-F depict qRT-PCR graphs illustrating the expression levels of endogenous iPSC markers, namely bSOX2 (Fig.4C), bOCT4 (Fig.4D), bNANOG (FIG.4E), and bSALL4 (Fig. 4F), following five factor (5F) reprogramming process (5F iPSC pool), as well as their parental untreated fibroblast-like cells (fib-like cells) in three biological replicates (1,2,3).

[0084] Figs. 5A-5C show the ability of reprogramming factors combinations to produce iPSCs, when introduced into bovine cells. The baseline factors combination comprises the following 7 (seven) factors hOCT4, hSOX2-17 (or hSOX2-VP160), hKLF4, hLIN28A, hMYCL, bNANOG, hSALL4 (7F). Fig. 5A shows representative bright-field imagesshowing the reprogramming outcomes for each indicated factor combination following three weeks of reprogramming. The 7F factors combination was introduced into bovine embryonic myoblasts (bEM) with the addition of either of hPRDM14, hH-RAS, hMYC, hTFAP2C, hJDP2, P53DD, P53DD+hJDP2, or hPRDM14+P53DD+hJDP2 (10F) (row by row, starting from the top left and moving from left to right in each row). Fig. 5B shows the quantification of colony formation efficacy, summarizing the number of colonies observed for each condition (7F +) shown in Fig 5A. Fig. 5C shows bright field images of iPSCs derived from using the 10F combination (hOCT4, hSOX2-17, hKEF4, hLIN28A, hMYCL, bNANOG, hSALL4, hPRDM14, P53DD and hJDP2) in bEM and bovine embryonic fibroblast (bEF) cells.

[0085] Fig.6 shows the ability of reprogramming factors combinations and agents inhibiting p53 and API to produce iPSCs, when introduced into bovine cells. The factors combination comprises the following 7 (seven) factors hOCT4, hSOX2-17, hKLF4, hLIN28A, hMYCL, P53DD and hJDP2.

[0086] DETAILED DESCRIPTION OF THE INVENTION

[0087] Producing mammalian, and specifically bovine induced pluripotent stem cells (iPSCs) from somatic cells poses a significant challenge. As shown in the examples, previous attempts using conventional reprogramming combinations, including the use of the well-known reprogramming factors OS KM (Oct4, Sox2, Klf4, and c-Myc), NANOG, LIN28, and others, have thus far proven unsuccessful.

[0088] The present invention provides, inter alia, a novel minimal combination of at least five reprogramming factors, shown to be capable to produce iPSCs from bovine somatic cells. This is the first time that the reprogramming factors from SALL and PRDM family are being used to produce bovine iPSCs as well as the novel chimeric SOX2-VP160 polypeptide.

[0089] The inventors of the present invention conducted comprehensive analyses, including RNA-seq, ATAC-seq, ChlP-seq (H3K4me2), and RRBS on four different bovine somatic cell types (bovine embryonic fibroblasts [BEF], bovine embryonic myoblasts [BEM], mesenchymal stem cells [MSC], and endothelial progenitor cells [EPC]) and compared them to bovine embryonic stem cells (ESCs), in order to betterunderstand the factors influencing the reprogramming process in bovine somatic cells. These analyses revealed unique factors and signaling pathways that are active in the bovine pluripotent state, setting it apart from other species such as humans and mice. The method of the present invention was shown to be effective on cells that were previously demonstrated as being refractory to reprograming by the original four genes of Yamanaka (Oct4, Sox2, Klf4, and cMyc)

[0090] Definitions

[0091] The term mammals and mammalian refers to all mammals - human and nonhuman mammals. The term includes humans, primates, livestock animals (including bovines, porcine, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).

[0092] According to some embodiments, the non-human mammal is selected from the group consisting of livestock animals, domestic pets, rodents, wild animals, and primate. In one embodiment the livestock animals is selected from cattle, pigs, sheep, goats, horses, mules, asses, buffalo, and camels. In some other embodiments, the domestic pet is a cat or dog, the rodent is a rat, mice guinea pig or hamster, the lagomorpha is a rabbit, and the primate is monkey such as macaques or ape embryo such as chimpanzee.

[0093] The term "bovine" is used herein according to its broadest meaning in the Art. According to certain embodiments, the term "bovine"(subfamily Bovinae) comprises a diverse group of 10 genera of medium to large-sized ungulates, including cattle, bison, African buffalo, water buffalos, and the four-horned and spiral-horned antelopes.

[0094] As used herein the term “polynucleotide” refers to a single or double stranded nucleic acid sequence which is isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a DNA sequence and / or composite polynucleotide sequences (e.g., a combination of the above).

[0095] The terms “protein” and “polypeptide” are used interchangeably herein to designate a series of amino acid residues, connected to each other by peptide bonds between the alpha-amino and carboxyl groups of adjacent residues. The terms “protein” and “polypeptide” refer to a polymer of amino acids, including modified amino acids (e.g., phosphorylated, glycated, glycosylated, etc.) and amino acid analogs, regardless of its size or function. “Protein” and “polypeptide” are often used in reference to relatively largepolypeptides, whereas the term “peptide” is often used in reference to small polypeptides, but usage of these terms in the art overlaps. The terms “protein” and “polypeptide” are used interchangeably herein when referring to a gene product and fragments thereof. Thus, exemplary polypeptides or proteins include gene products, naturally occurring proteins, homologs, orthologs, paralogs, fragments and other equivalents, variants, fragments, and analogs of the foregoing.

[0096] As used herein, the term “exogenous” means originating from outside a particular organism, cell, tissue, or system, rather than being naturally produced within it. As such "exogenous sequence" refers to sequence that was not present originally in the protein or gene. As used herein, the term “exogenous polynucleotide” refers to a heterologous nucleic acid sequence which is not naturally present within a cell, such as in a somatic cell (e.g., a nucleic acid sequence from a different species). The exogenous polynucleotide may be introduced into the bovine cell in a stable manner, by integrating into the cell genome or in a transient manner, using non-integrating expression tools so as to produce a ribonucleic acid (RNA) molecule and / or a polypeptide molecule.

[0097] The term "endogenous” as used herein refers to a polynucleotide or polypeptide which is naturally present and / or naturally expressed within a cell.

[0098] The term "inbred beef" is used as commonly known in the art and refers to beef obtained from cattle lines that have undergone controlled inbreeding (e.g., mating of related individuals such as half-siblings, cousins, or progeny to parent), where the coefficient of inbreeding has been increased above that typical of outbred populations. Such inbred lines display increased homozygosity and reduced genetic variation, and the term encompasses beef derived from animals with a defined pedigree that meets the inbreeding criteria utilized in animal breeding programs. Typically, somatic cells from inbred beef are more resistant to reprogramming than outbred beef. Therefore, according to the teaching of the present invention the somatic cells from inbred beef are refractory to reprograming by methods known in the art, e.g. by four reprogramming factors Oct4, Sox2, Klf4, and cMyc.

[0099] According to one aspect, the present invention provides a method of producing a mammalian induced pluripotent stem cells (iPSCs), the method comprising introducing into the mammalian somatic cells at least one exogenous polynucleotide encoding five ormore reprogramming factors, wherein the five reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family, thereby producing a mammalian iPSCs. The method refers to preparation of one or more mammalian iPSC. Therefore, according to some embodiments, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs), the method comprising introducing into one or more mammalian somatic cells at least one exogenous polynucleotide encoding five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family, thereby producing one or more mammalian iPSCs. According to some embodiments, the at least two reprogramming factors are from different families, e.g. NANOG and a factor from SALL family; NANOG and a factor from PRDM family; or a factor from SALL family and a factor from PRDM family.

[0100] According to some embodiments, the mammalian somatic cell is a somatic cell of a mammal selected from selected from a livestock animals (including bovines, porcine, etc.), humans, primates, companion animals (e.g., canines, felines, etc.) and rodents. According to some embodiments, the mammalian somatic cell is a cells of a livestock animal. According to some embodiments, the livestock animals is selected from cattle, pigs, sheep, goats, horses, mules, asses, buffalo, and camels. According to some embodiments, the mammalian somatic cell is a bovine somatic cell. Therefore, according to some embodiments, the present invention provides a method of producing one or more bovine induced pluripotent stem cells (iPSCs), the method comprising introducing into one or more bovine somatic cells at least one exogenous polynucleotide encoding five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family, thereby producing one or more bovine iPSCs. According to some embodiments, the mammalian somatic cells are refractory to reprograming by the original four genes of Yamanaka: Oct4, Sox2, Klf4, and cMyc.According to the teaching of the present invention all terms referred to proteins, reprogramming factors and agents having a biological activity refer to their commonly known names and properties.

[0101] According to certain embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, a chimeric SOX2, a factor of the KLF family, NANOG and a factor of the SALL family.

[0102] According to certain embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, a chimeric SOX2, a factor of the KLF family, NANOG and a factor of the PRDM family.

[0103] According to certain embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, a chimeric SOX2, a factor of the KLF family, a factor of the SALL family and a factor of the PRDM family.

[0104] According to certain embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family and a factor of the PRDM family.

[0105] The term "chimeric SOX2" refers to SOX2 protein or to a truncate SOX2 protein comprising one or more exogenous transactivation domains (AD). The term "truncated SOX2" refers to SOX2 lacking its (SOX2's) transactivation domain. In some embodiments, the chimeric SOX2 comprises truncated SOX2 comprising one or more exogenous transactivation domain (instead the transactivation domain of SOX2). In some embodiments, the chimeric SOX2 comprises one or more exogenous transactivation domains in addition to the transactivation domain of SOX2.

[0106] Various transactivation domains that may enhance SOX2 reprogramming activity can be used according to the teachings of the present invention. According to certain embodiments, the exogenous transactivation domain is a transactivation domain of a protein selected from the group consisting of SOX17, VP16, VP, Gal4, P53, Estrogen Receptor, NFkB CREB, and MYOD. According to certain embodiments, the exogenous transactivation domain is derived from a protein selected from the group consisting of SOX17, VP16, VP, Gal4, P53, Estrogen Receptor, NFkB CREB, and MYOD. Each possibility represents a separate embodiment of the present invention. In some embodiments, the chimeric SOX2 comprises SOX2 or a truncated SOX2 and from 1 to20 copies of the exogenous transactivation domain selected from a transactivation domain of a protein selected from the group consisting of SOX17, VP16, VP, Gal4, P53, Estrogen Receptor, NFkB CREB, and MYOD. In some embodiments, the chimeric SOX2 comprises from 2 to 16 copies of the exogenous transactivation domain. In some embodiments, the chimeric SOX2 comprises from 6 to 12 copies of the transactivation domain.

[0107] According to certain embodiments, the P53 transactivation domain is selected from the group consisting activation domain (AD)-l and AD2. Each possibility represents a separate embodiment of the present invention.

[0108] According to certain embodiments, the transactivation domain is derived from a protein selected from the group consisting VP16, VP48, VP64 and SOX17. Each possibility represents a separate embodiment of the present invention.

[0109] According to certain exemplary embodiments, the transactivation domain is the activation domain of VP16. In some embodiments, the chimeric SOX2 comprises SOX2 and from 1 to 20 copies of the transactivation domain of VP 16. In some embodiments, the chimeric SOX2 comprises from 2 to 16 copies of the transactivation domain of VP16. In some embodiments, the chimeric SOX2 comprises from 6 to 12 copies of the transactivation domain of VP16. In some embodiments, the chimeric SOX2 comprises from 8 to 12 copies of the transactivation domain of VP16. In some embodiments, the chimeric SOX2 comprises from 10 copies of the transactivation domain of VP16. According to certain embodiment, a repeat of 10 VP16 AD (VP160) is used and referred to as SOX2-VP160. According to some embodiments, the SOX2-VP160 comprises an amino acid sequence SEQ ID NO: 1 or a functional analog thereof.

[0110] In some embodiments, the chimeric SOX2 is a truncated SOX2 comprising from 1 to 20 copies of the transactivation domain of SOX17. According to some embodiments, the chimeric SOX2 comprises from 2 to 16, from 6 to 12, from 8 to 12, from 1 to 4, from or from 1 to 3 copies of the transactivation domain of SOX17. According to some embodiments, the chimeric SOX2 comprises a truncated SOX2 fused to one copy of the transactivation domain of SOX 17 and referred to as SOX2-17. According to some embodiments, the SOX2-VP160 comprises an amino acid sequence encoded by the nucleic acid sequence SEQ ID NO:90, or a functional analog thereof.According to any one of the embodiments of the invention, the factor of the KLF family is selected from the group consisting of KLF4, KLF5, KLF2, KLF6 and KLF17. Each possibility represents a separate embodiment of the present invention.

[0111] According to certain exemplary embodiments, the factor of the KLF family is KLF4.

[0112] According to any one of the embodiments of the invention, the factor of the SALL family is selected from the group consisting of SALL4, SALL1, SALL2 and SALL3. Each possibility represents a separate embodiment of the present invention.

[0113] According to certain exemplary embodiments, the factor of the SALL family is SALL4.

[0114] According to any one of the embodiments of the invention, the factor of the PRDM family is selected from the group consisting of PRDM14 and PRDM1. Each possibility represents a separate embodiment of the present invention.

[0115] According to certain exemplary embodiments, the factor of the PRDM family is PRDM 14.

[0116] According to certain embodiments, the method of producing one or more mammalian induced pluripotent stem cells (iPSCs) comprises introducing at least one exogenous polynucleotide encoding OCT4, a chimeric SOX2, KLF4, NANOG, SALL4 and PRDM14. According to certain embodiments, the chimeric SOX2 is SOX2-VP160. According to certain embodiments, the chimeric SOX2 is SOX2-17.

[0117] According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, SOX2-VP160, KLF4, NANOG and PRDM14.

[0118] According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, SOX2-VP160, KLF4, NANOG and SALL4.

[0119] According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, SOX2-VP160, KLF4, SALL4 and PRDM14.According to certain currently exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, SOX2-VP160, KLF4, NANOG, SALL4 and PRDM14.

[0120] According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, SOX2-17, KLF4, NANOG and PRDM14.

[0121] According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, SOX2-17, KLF4, NANOG and SALL4.

[0122] According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, SOX2-17, KLF4, SALL4 and PRDM14.

[0123] According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, SOX2-17, KLF4, SALL4, NANOG and PRDM14.

[0124] According to any one of the above embodiments, the method further comprises introducing into the one or more mammalian somatic cells at least one exogenous polynucleotide encoding an additional reprograming factors selected from the group consisting of a factor of the LIN28 family, a factor of the MYC family and a combination of factors of LIN28 family and MYC family.

[0125] According to certain embodiments, the factor of the LIN28 family is LIN28A. According to certain embodiments, the factor of the LIN28 family is LIN28B.

[0126] According to certain embodiments, the factor of the MYC family is selected from the group consisting of MYCL, MYCN, MYBL2, and c-MYC. Each possibility represents a separate embodiment of the present invention. According to certain embodiments, the factor of the MYC family is MYCL. The terms "MYCL", "MYC-L" and" L-MYC" are used herein interchangeably as terms "MYCN", "MYC-N" and "N-MYC".

[0127] According to some embodiments, the factors of LIN28 family and MYC family may be used instead of the at least two reprogramming factors selected from the groupconsisting of NANOG, a factor of the SALL family and a factor of the PRDM family. Therefore, according to some embodiment, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs), the method comprising introducing into one or more mammalian somatic cells at least one exogenous polynucleotide encoding five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, a factor of the LIN28 family, a factor of the MYC family.

[0128] According to any one of the above embodiments, the method further comprises introducing into the one or more mammalian somatic cells at least one exogenous polynucleotide encoding at least one agent downregulating a transcription factor or its activity, wherein the agent downregulating a transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. The term "an agent downregulating a transcription factor" encompasses agents reducing the activity of the transcription factor as well agents downregulating or silencing the expression and / or transcription of the transcription factor, as known int the art.

[0129] According to some embodiments, an agent downregulating p53 transcription factor is a p53 suppressor selected form p53 dominant-negative mutant of p53 (p53DD), MDM2, HPV E6 Protein, GSE56, p53-silencing molecule selected from the group consisting of p53 siRNA, shp53, CRISPR / Cas9 mediating p53 silencing, and the like. According to some embodiments, an agent downregulating p53 transcription factor is p53DD. According to some embodiments, an agent downregulating p53 transcription factor is shp53. According to some embodiments, an agent downregulating p53 transcription factor is GSE56.

[0130] According to certain embodiments, the AP-1 downregulating agent is selected from an agent downregulating c-FOS and / or c-JUN. According to certain embodiments, the agent is selected from the group consisting JDP2, BATE, c-FOS / c-JUN siRNA, sh c-FOS / c-JUN, CRISPR / Cas9 mediating c-FOS / c-JUN silencing, c-FOS / c-JUN-silencing molecule. Each possibility represents a separate embodiment of the present invention. According to certain embodiments, the agent is JDP2. According to certain embodiments, the agent is shFOS. According to certain embodiments, the agent is shJUN.

[0131] According to any one of the above embodiments, the method further comprisesintroducing into the one or more mammalian somatic cells at least one exogenous polynucleotide encoding p53DD or shp53, and JDP2 or shFOS or shJUN.

[0132] In some embodiments, the at least one exogenous polynucleotide may the same polynucleotide encoding the reprograming factors and the downregulating agents described hereinabove, or the transcription factors and the down-regulating agent(s) may be encoded by separate exogenous polynucleotide.

[0133] According to some embodiments, the five or more reprogramming factor combination is devoid of an exogenous polynucleotide encoding a member of the reprogramming factor LIN28 family. According to some embodiments, the five or more reprogramming factor combination is devoid of an exogenous polynucleotide encoding the reprogramming factor Lin28A polypeptide. According to some embodiments, the five or more reprogramming factor combination is devoid of an exogenous polynucleotide encoding the reprogramming factor MYCL.

[0134] According to certain embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, and a downregulating agent of the transcription factor p53.

[0135] According to certain embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, and a downregulating agent of the transcription factor AP-1 or a part thereof.

[0136] According to certain embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, a factor of the PRDM family, and downregulating agents of the transcription factors p53 and AP-1 or a part thereof.

[0137] According to certain embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, a factor of the PRDM family, and downregulating agents of the transcription factors p53 and AP-1 or a part thereof, and a factor of LIN28 family.According to certain embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, a factor of the PRDM family, and downregulating agents of the transcription factors p53 and AP-1 or a part thereof, a factor from LIN28 family, and a factor from MYC family.

[0138] According to some embodiments, the combination of one or more reprogramming factors may comprise or be devoid of an exogenous polynucleotide encoding a member of the reprogramming factor LIN28 family. According to some embodiments, the combination of one or more reprogramming factors may comprise or be devoid of an exogenous polynucleotide encoding the reprogramming factor LIN28A polypeptide.

[0139] According to some embodiments, the combination of one or more reprogramming factors may comprise or be devoid of an exogenous polynucleotide encoding the reprogramming factor MYCL.

[0140] According to some embodiment, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs), the method comprising introducing into one or more mammalian somatic cells at least one exogenous polynucleotide encoding five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, a factor of the LIN28 family, a factor of the MYC family, and an agent downregulating p53 and an agent downregulating AP-1. According to some embodiments, the agent downregulating p53 is p53DD or shp53, and the agent downregulating AP-1 is JDP2 or shFOS or shJUN. According to some embodiment, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs), the method comprising introducing into one or more mammalian somatic cells at least one exogenous polynucleotide encoding five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, a factor of the LIN28 family, a factor of the MYC family, p53DD and JDP2. According to some embodiments, the chimeric SOX2 is chimeric SOX2-VP160. According to some embodiments, the chimeric SOX2 is chimeric SOX2-17.

[0141] According to some embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4,chimeric S0X2, KLF4, NANOG, and PRDM14. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14 and at least one agent downregulating a transcription factor or its activity, wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14 and at least one of JDP2, shFOS and shJUN. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, p53DD or shp53, or GSE56 and JDP2 or shFOS, or shJUN. According to certain exemplary embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14 and LIN28A. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14 and MYCL. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, LIN28A and MYCL. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL and at least one agent downregulating a transcription factor or its activity wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and JDP2. According tosome embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53 and JDP2. According to any one of the above embodiments, an agent inhibiting p53 is GSE56. According to any one of the above embodiments, an agent inhibiting API is shFOS or shJUN. According to some embodiments, one or more agent inhibiting API and / or one or more agent inhibiting p53 may be used. According to some embodiments, the chimeric SOX2 is SOX2-VP160. According to some embodiments, the chimeric SOX2 is SOX2-17. According to some embodiments, the mammalian somatic cell is a bovine somatic cell. According to some embodiments, the bovine somatic cell are cells of inbred beef. According to some embodiments, the bovine somatic cell are cells of outbred beef.

[0142] According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG and SALL4. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and at least one agent downregulating a transcription factor or its activity, wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and JDP2. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, p53DD or shp53, and JDP2. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG and SALL4. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and LIN28A. According to some embodiments, the method comprises introducing at least one exogenouspolynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and MYCL. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, LIN28A and MYCL. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and at least one agent downregulating a transcription factor or its activity wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and JDP2. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53 and JDP2. According to some embodiments, the chimeric SOX2 is SOX2-VP160. According to any one of the above embodiments, an agent inhibiting p53 is GSE56. According to any one of the above embodiments, an agent inhibiting API is shFOS or shJUN. According to some embodiments, one or more agent inhibiting API and / or one or more agent inhibiting p53 may be used. According to some embodiments, the chimeric SOX2 is SOX2-17. According to some embodiments, the mammalian somatic cell is a bovine somatic cell. According to some embodiments, the bovine somatic cell are cells of inbred beef. According to some embodiments, the bovine somatic cell are cells of outbred beef.

[0143] According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4 and PRDM14. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14 and at least one agent downregulating a transcription factor or its activity, wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof.According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14 and JDP2. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, p53DD or shp53, and JDP2. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14 and LIN28A. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14 and MYCL. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, LIN28A and MYCL. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and at least one agent downregulating a transcription factor or its activity wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and JDP2. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53 and JDP2. According to some embodiments, the chimeric SOX2 is SOX2-VP160. According to some embodiments, the chimeric SOX2 is SOX2-17. According to any one of the above embodiments, an agent inhibiting p53 is GSE56. According to any one of the aboveembodiments, an agent inhibiting API is shFOS or shJUN. According to some embodiments, one or more agent inhibiting API and / or one or more agent inhibiting p53 may be used. According to some embodiments, the mammalian somatic cell is a bovine somatic cell. According to some embodiments, the bovine somatic cell are cells of inbred beef. According to some embodiments, the bovine somatic cell are cells of outbred beef.

[0144] According to certain currently exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and PRDM14. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14 and at least one agent downregulating a transcription factor or its activity, wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14 and JDP2. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, p53DD or shp53, and JDP2. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14 and LIN28A. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14 and MYCL. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, LIN28A and MYCL. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and at least one agent downregulating a transcription factor or its activity,wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and JDP2. According to some embodiments, the method comprises introducing at least one exogenous polynucleotide encoding OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53 and JDP2. According to any one of the above embodiments, an agent inhibiting p53 is GSE56. According to any one of the above embodiments, an agent inhibiting API is shFOS or shJUN. According to some embodiments, one or more agent inhibiting API and / or one or more agent inhibiting p53 may be used. According to some embodiments, the chimeric SOX2 is chimeric SOX2-VP160. According to some embodiments, the chimeric SOX2 is chimeric SOX2-17. According to some embodiments, the mammalian somatic cell is a bovine somatic cell. According to some embodiments, the bovine somatic cell are cells of inbred beef. According to some embodiments, the bovine somatic cell are cells of outbred beef.

[0145] According to some embodiment, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs), the method comprising introducing into one or more mammalian somatic cells at least one exogenous polynucleotide encoding five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, a factor of the LIN28 family, a factor of the MYC family, p53DD and JDP2. According to some embodiments, the chimeric SOX2 is chimeric SOX2-VP160. According to some embodiments, the chimeric SOX2 is chimeric SOX2-17. According to some embodiments, the mammalian cells are bovine cells. According to some embodiments, the bovine somatic cell are cells of inbred beef. According to some embodiments, the bovine somatic cell are cells of outbred beef.

[0146] According to any one of the above aspects and embodiments, the nucleic acid molecule of the present invention comprises at least one of the sequences selected fromSEQ ID NO: 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, and a nucleic acid encoding SEQ ID NO: 1 or a variant thereof.

[0147] The combination of reprogramming factors may be introduced into the one or more mammalian somatic cells by introducing one or more polynucleotides encoding said reprogramming factor combination.

[0148] According to certain embodiments, the combination of reprogramming factors and optionally an agent downregulating a transcription factor is encoded by a single polynucleotide. According to these embodiments, the method comprises introducing into one or more mammalian somatic cells a single polynucleotide encoding the five or more reprogramming factors and optionally an agent downregulating a transcription factor.

[0149] According to certain embodiments, one or more reprogramming factors are encoded by one or more polynucleotides. According to certain embodiments, one or more an agent downregulating a transcription factors are encoded by one or more polynucleotides. According to these embodiments, the method comprises introducing into the one or more mammalian somatic cells a plurality of polynucleotides, wherein each of the plurality of polynucleotides encodes one or more reprogramming factors and optionally an agent downregulating a transcription factor.

[0150] According to certain embodiments, each of the reprogramming factor is encoded by a separate polynucleotide. According to these embodiments, the method comprises introducing into one or more mammalian somatic cells a plurality of polynucleotides, each encoding a single reprogramming factor. According to these embodiments, the method comprises introducing into one or more mammalian somatic cells a plurality of polynucleotides, each encoding at least a single reprogramming factor. According to these embodiments, the method comprises introducing into one or more mammalian somatic cells a plurality of polynucleotides, encoding two, three, four, five, six, seven, or eight reprogramming factors and / or downregulating a transcription factor.

[0151] Any appropriate method can be used to introduce the exogenous polynucleotide(s) of the invention into a bovine cell. For example, the polynucleotide(s) can be transferred to the cells using recombinant viruses that can infect cells, or liposomes or other non-viral methods such as electroporation, microinjection, transposons, phage integrases, or calcium phosphate precipitation, that are capable of delivering nucleic acids to bovinecells.

[0152] The exogenous nucleic acid that is delivered typically is part of a vector in which a regulatory element such as a promoter is operably linked to the polynucleotide of interest.

[0153] The promoter can be constitutive or inducible. Non-limiting examples of constitutive promoters include cytomegalovirus (CMV) promoter and the Rous sarcoma virus promoter. As used herein, "inducible" refers to both up-regulation and down regulation. An inducible promoter is a promoter that is capable of directly or indirectly activating transcription of one or more DNA sequences or genes in response to an inducer. In the absence of an inducer, the DNA sequences or genes will not be transcribed. The inducer can be a chemical agent such as a protein, metabolite, growth regulator, phenolic compound, or a physiological stress imposed directly by, for example heat, or indirectly through the action of a pathogen or disease agent such as a virus.

[0154] Additional regulatory elements that may be useful in vectors to obtain optimal expression of the polynucleotide(s) in the cells, include, but are not limited to, polyadenylation sequences, translation control sequences (e.g., an internal ribosome entry segment, IRES), self-cleavage sequences such as 2A (e.g. P2A, E2A, F2A, and T2A), enhancers, or introns. Such elements may not be necessary, although they can increase expression by affecting transcription, stability of the mRNA, translational efficiency, or the like.

[0155] Vectors suitable for use according to the teachings of the present invention can include a nucleic acid encoding a signal peptide for directing the encoded protein to a particular cellular location (e.g., the cell surface) or a nucleic acid encoding a selectable marker. Non-limiting examples of selectable markers include puromycin, adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo, G418, APH), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase, thymidine kinase (TK), and xanthin-guanine phosphoribosyltransferase (XGPRT). Selectable markers are useful for selecting stable transformed cells in culture.

[0156] According to certain embodiments, the at least one exogenous polynucleotide is a gene-delivery and / or expression vector comprising a nucleic acid sequence encoding the at one or more reprogramming factor of the invention. According to exemplary embodiments, the gene-delivery and / or expression vector is selected from the groupconsisting of integrating vector and non-integrating vector.

[0157] Using a non-integrating vector or other non-integrating polynucleotides has the advantage of producing non-genetically modified iPSCs, which are preferable for use in the food industry.

[0158] According to certain embodiments, the non-integrating vector is selected from the group consisting of episomal vector, Sendai virus (SeV) vector, and adenovirus vector. Each possibility represents a separate embodiment of the present invention.

[0159] According to certain embodiment, the at least one polynucleotide comprises an mRNA encoding the one or more reprogramming factor.

[0160] It is to be explicitly understood that integrating polynucleotides may be also used according to the teachings of the present invention.

[0161] According to certain embodiments, the integrating vector is selected from the group consisting of lentiviral and retroviral vectors.

[0162] The cells comprising the introduced exogenous one or more polynucleotides are cultured under conditions suitable for obtaining a population of induced pluripotent stem cells, including serum-containing and serum-free media. According to certain embodiments, the cells are grown on a fibroblast medium (FM-2or DMEM containing, 5% FBS, 1% fibroblast growth supplement-2, and 1% antibiotic solution (P / S) for 5 days. Then, cells were transferred to feeder-free maintenance medium (containing half fibroblast medium described above and half bESC medium (mTeSR + Wnt inhibitor (2.5p.M IWR-1) for 2 days, and thereafter are grown on bESC medium for 8 days and transferred to feeder coated wells in the same media.

[0163] According to any one of the embodiments of the present invention, the reprogramming factors are of a mammalian factors. According to certain embodiments, the mammalian reprogramming factors are selected from human reprogramming factors, murine reprogramming factors, ungulate reprogramming factors and a combination thereof. According to certain embodiments, the ungulate reprogramming factors are bovine. According to some embodiments, the encoded reprogramming factors are of a mammalian origin. According to certain embodiments, the encoded reprogramming factors are of an origin selected from the group consisting of human origin, murine originand ungulate origin. According to certain embodiments, the ungulate is bovine. According to some embodiments, the reprogramming factors are human factors. According to some embodiments, the reprogramming factors are bovine factors. According to some embodiments, the reprogramming factors are a combination of human and bovine factors. According to some embodiments, the reprogramming factors are a combination of human, bovine factors and murine factors.

[0164] According to certain embodiments, the encoded reprogramming factors are of human origin. According to certain exemplary embodiments, the OCT4 protein is encoded by a gene having Gene Bank Accession No. ENSG00000204531 and comprising an amino acid sequence encoded by that gene and having UniProtKB identifier: Q01860; the SOX2 protein is encoded by a gene having Gene Bank Accession No. ENSG00000181449 and comprising an amino acid sequence encoded by that gene and having UniProtKB identifier P48431 ; the KLF4 protein is encoded by a gene having Gene Bank Accession No. ENSG00000136826 and comprising an amino acid sequence encoded by that gene and having UniProtKB identifier 043474; the SALL4 protein is encoded by a gene having Gene Bank Accession No. ENSG00000101115 and comprising an amino acid sequence encoded by that gene and having UniProtKB identifier Q9UJQ4; the NANOG protein is encoded by a gene having Gene Bank Accession No. ENSG00000111704 and comprising an amino acid sequence encoded by that gene and having UniProtKB identifier Q9H9S0; and the PRDM14 protein is encoded by a gene having Gene Bank Accession No. ENSG00000147596 and comprising an amino acid sequence encoded by that gene and having UniProtKB identifier Q9GZV8.

[0165] According to certain embodiments, the encoded reprogramming factors are bovine factors. According to certain exemplary embodiments, the OCT4 is encoded by a gene having Gene Bank Accession No. ENSBTAG00000021111; the SOX2 is encoded by a gene having Gene Bank Accession No. ENSBTAG00000063362; the KLF4 protein is encoded by a gene having Gene Bank Accession No. ENSBTAG00000020355; the SALL4 protein is encoded by a gene having Gene Bank Accession No. ENSBTAG00000003101; the NANOG protein is encoded by a gene having Gene Bank Accession No. ENSBTAG00000020916 and comprising an amino acid sequence encoded by that gene and having UniProtKB identifier Q4JM65; and the PRDM14 protein is encoded by a gene having Gene Bank Accession No. ENSBTAG00000000060.According to certain exemplary embodiments, the chimeric SOX2 comprises an amino acid sequence at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 90% homologous to SEQ ID NO: 1.

[0166] According to certain embodiments, the chimeric SOX2 comprises the amino acid sequence set forth in SEQ ID NO: 1. According to some embodiments, the nucleic acid encoding a chimeric SOX2 comprises a nucleic acid sequences encoding the amino acid sequence SEQ ID NO: 1.

[0167] According to any one of the aspects and embodiments of the invention, the mammalian somatic cells are bovine somatic cells. According to certain embodiments, the bovine somatic cell is selected from the group consisting of Bovine fibroblast-like cells, Bovine embryonic myoblasts (bEM), Bovine fibroblasts, Bovine Embryonic Myoblasts (BEM), Adipose tissue-derived bovine Mesenchymal Stem Cells (bMSCs), Bovine satellite cells (Bsh3), Bovine Endothelial Progenitor Cells (bEPCs), and Bovine cord lining cells (BCL2A). Each possibility represents a separate embodiment of the present invention.

[0168] According to certain embodiments, the fibroblast cell is Bovine Embryonic Fibroblasts (BEF). According to certain embodiments as exemplified hereinbelow, the fibroblast cell is bovine dermal fibroblasts (BDF). According to additional or alternative embodiments exemplified hereinbelow, the fibroblast-like cell is a mesenchymal cell differentiated from ESCs obtained from cattle. According to certain embodiments, the cattle is of the Angus breed. According to some embodiments, the bovine somatic cells are from inbred breeds of beefs. According to some embodiments, the bovine somatic cells are from inbreed cattle. According to some embodiments, the bovine somatic cells are from outbred cattle. Typically, somatic cells from inbreed require more reprogramming factors and an agent downregulating a transcription factors to produce iPSC.

[0169] According to certain embodiments, the bovine cells are derived from bovine livestock, particularly cow, that is bred and raised for meat production. Using a bovine livestock as a cell source is advantageous in the food industry, answering the regulatoryrequirements of this industry. According to any one of the aspects and embodiments of the invention, the mammalian somatic cells are bovine somatic cells.

[0170] The one or more bovine somatic cells that may be used according to the method of the present invention can be fresh cells or cells obtained from a frozen stock. The cells may be somatic or non-pluripotent progenitor cells directly derived from a bovine tissue or somatic / progenitor cells differentiated from embryonic stem cells derived from a bovine blastocyst.

[0171] According to some embodiments, the mammalian somatic cells are selected from peripheral blood cells, mesenchymal stem cells, fibroblasts, keratinocytes, urine-derived and epithelial cells. According to some embodiments, the mammalian somatic cells are peripheral blood cells. According to some embodiments, the mammalian somatic cells are mesenchymal stem cells. According to some embodiments, the mammalian somatic cells are fibroblasts. According to some embodiments, the mammalian somatic cells are embryonic cells.

[0172] According to any one of the above embodiments, the method further comprises growing the iPSC. The terms “growth” and "growing" of cells as used herein encompass any of the following: proliferation, maturation, propagation, and support of cells. Therefore, according to some embodiments, the method further comprises proliferation of mammalian iPSC. According to some embodiments, the method further comprises differentiation of the iPSC into mammalian somatic cells.

[0173] According to another aspect, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs) comprising introducing into one or more mammalian somatic cells five or more reprogramming factor proteins, wherein the five reprogramming factor proteins comprise OCT4, chimeric SOX2 and a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM. According to some embodiments, the present invention provides a method of producing a mammalian induced pluripotent stem cells (iPSCs) comprising introducing into a mammalian somatic cells a combination of five or more reprogramming factor proteins, wherein the combination of five reprogramming factor proteins comprises OCT4, chimeric SOX2 and a factor of the KLF family, and at least two reprogramming factorsselected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM. According to some embodiments, the at least two reprogramming factors are from different families, e.g. NANOG and a factor from SALL family; NANOG and a factor from PRDM family; or a factor from SALL family and a factor from PRDM family. According to another embodiments, the mammalian somatic cell is a cells of a livestock animal. According to some embodiments, the mammalian somatic cells are resistant to reprograming by factors Oct4, Sox2, Klf4, and cMyc. According to some embodiments, the livestock animals is selected from cattle, pigs, sheep, goats, horses, mules, asses, buffalo, and camels. According to some embodiments, the mammalian somatic cell is a bovine somatic cell. Therefore, according to some embodiments, the present invention provides a method of producing one or more bovine induced pluripotent stem cells (iPSCs), the method comprising introducing into one or more bovine somatic cells a combination of five or more reprogramming factor proteins, wherein the five reprogramming factor proteins comprise OCT4, chimeric SOX2 and a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family, thereby producing one or more bovine iPSCs.

[0174] All terms, embodiments and definitions disclosed in any one of the above aspects apply and are encompassed herein as well.

[0175] According to certain embodiments, the method comprises introducing the exogenous reprogramming factors OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family and a factor of the PRDM family.

[0176] According to certain embodiments, the method comprises introducing the exogenous reprogramming factors OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, and a factor of the SALL family.

[0177] According to certain embodiments, the chimeric SOX2 comprises SOX2 or a truncated SOX2 and one or more copies of an exogenous transactivation domain (AD). According to certain embodiments, the transactivation domain is derived from a protein selected from the group consisting of SOX17, VP16, VP, Gal4, P53, Estrogen Receptor, NFkB CREB, and MYOD. Each possibility represents a separate embodiment of the present invention. In some embodiments, the chimeric SOX2 comprises SOX2 or atruncated S0X2 and from 1 to 20 copies of the transactivation domain. In some embodiments, the chimeric SOX2 comprises from 2 to 16 copies of the transactivation domain. In some embodiments, the chimeric SOX2 comprises from 6 to 12 copies of the transactivation domain.

[0178] According to certain embodiments, the P53 transactivation domain is selected from the group consisting activation domain (AD)-l and AD2. Each possibility represents a separate embodiment of the present invention.

[0179] According to certain embodiments, the trans-activation domain is derived from a protein selected from the group consisting VP16, VP48, VP64 and SOX17. Each possibility represents a separate embodiment of the present invention.

[0180] According to certain exemplary embodiments, the transactivation domain is the activation domain of VP 16. According to certain embodiment, a at least one VP 16 AD is used. According to certain embodiment, a repeat of at least 10 VP16 AD (VP160) is used. According to certain embodiment, a repeat of at least 20 VP 16 AD is used. According to certain embodiment, a repeat of at least 30 VP16 AD is used. According to certain exemplary embodiments, a repeat of 10 VP16 AD (VP160) is used. According to certain embodiment, the number of VP 16 AD used is between the range of 1 to 30 copies. Each possibility represents a separate embodiment of the present invention. In some embodiments, the chimeric SOX2 comprises SOX2 and from 1 to 20 copies of the transactivation domain of VP16. In some embodiments, the chimeric SOX2 comprises from 2 to 16 copies of the transactivation domain of VP 16. In some embodiments, the chimeric SOX2 comprises from 6 to 12 copies of the transactivation domain of VP 16. In some embodiments, the chimeric SOX2 comprises from 8 to 12 copies of the transactivation domain of VP16. In some embodiments, the chimeric SOX2 comprises from 10 copies of the transactivation domain of VP16.

[0181] In some embodiments, the chimeric SOX2 is a truncated SOX2 comprising from 1 to 20 copies of the transactivation domain of SOX17. According to some embodiments, the chimeric SOX2 comprises from 2 to 16, from 6 to 12, from 8 to 12, from 1 to 4, from or from 1 to 3 copies of the transactivation domain of SOX17. According to some embodiments, the chimeric SOX2 comprises a truncated SOX2 and one copy of the transactivation domain of SOX 17 and referred to as SOX2-17.According to some embodiments, the factor of the KLF family is selected from the group consisting of KLF4, KLF5, KLF2, KLF6 and KLF17. Each possibility represents a separate embodiment of the present invention. According to certain exemplary embodiments, the factor of the KLF family is KLF4.

[0182] According to some embodiments, the factor of the SALL family is SALL4, SALL1, SALL2 and SALL3. Each possibility represents a separate embodiment of the present invention. According to certain exemplary embodiments, the factor of the SALL family is SALL4.

[0183] According to some embodiments, the factor of the PRDM family is PRDM14 and PRDM1. Each possibility represents a separate embodiment of the present invention. According to certain exemplary embodiments, the factor of the PRDM family is PRDM 14.

[0184] According to certain embodiments, the method comprises introducing the reprogramming factors OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, SALL4 and PRDM14.

[0185] According to certain embodiments, the five or more reprogramming factors introduced into one or more bovine somatic cells according to the teaching of the present invention may comprise or be devoid of an exogenous reprogramming factor LIN28A protein.

[0186] According to certain embodiments, the five or more reprogramming factors introduced into one or more bovine somatic cells according to the teaching of the present invention may comprise or be devoid of an exogenous reprogramming factor MYC protein.

[0187] According to certain embodiments, the method comprises introducing one or more additional exogenous reprograming factors selected from the group consisting of a factor of the LIN28 family, a factor of the MYC family, an agent downregulating at least one of P53 and / or AP-1 (Activator Protein- 1) or a part thereof, and any combination thereof.

[0188] According to certain embodiments, the factor of the LIN28 family is selected from the group consisting of LIN28A, and LIN28B. Each possibility represents a separate embodiment of the present invention.According to certain embodiments, the factor of the MYC family is selected from the group consisting of MYCL, MYCN, MYB2, and c-MYC. Each possibility represents a separate embodiment of the present invention.

[0189] According to some embodiments, the factors of LIN28 family and MYC family may be used instead of the at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family. Therefore, according to some embodiment, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs), the method comprising introducing into one or more mammalian somatic cells a combination of five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, a factor of the LIN28 family, a factor of the MYC family.

[0190] According to certain embodiments, the agent downregulating p53 is selected from the group consisting of p53 dominant-negative mutant of p53 (p53DD), GSE56, MDM2, HPV E6 Protein, p53-silencing molecule selected from the group consisting of p53 siRNA, shp53, CRISPR / Cas9 mediating p53 silencing, and the like. According to some embodiments, an agent downregulating p53 transcription factor is p53DD. According to some embodiments, an agent downregulating p53 transcription factor is shp53. According to some embodiments, an agent downregulating p53 transcription factor is GSE56.

[0191] According to certain embodiments, the agent downregulating AP-1 or a part thereof is selected from the group consisting of JDP2, BATF, c-FOS / c-JUN siRNA, sh c-FOS / c-JUN, CRISPR / Cas9 mediating c-FOS / c-JUN silencing, c-FOS / c-JUN-silencing molecule. Each possibility represents a separate embodiment of the present invention. According to certain embodiments, the agent is JDP2. According to certain embodiments, the agent is shFOS. According to certain embodiments, the agent is shJUN.

[0192] According to any one of the above embodiments, the method further comprises introducing into the one or more mammalian somatic cells at least one exogenous polynucleotide encoding p53DD or shp53, and JDP2 or shFOS or shJUN.

[0193] According to certain embodiments, the method comprises introducing the exogenous reprogramming factors OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, and p53DD.According to certain embodiments, the method comprises introducing the exogenous reprogramming factors OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, a factor of the PRDM family, p53DD and JPD2.

[0194] According to certain embodiments, the method comprises introducing the exogenous reprogramming factors OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, a factor of the PRDM family, p53DD, JPD2 and LIN28A.

[0195] According to certain embodiments, the method comprises introducing the exogenous reprogramming factors OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, a factor of the PRDM family, p53DD, JPD2, LIN28A, and MYCL.

[0196] According to some embodiments, the combination of one or more reprogramming factors may comprise or be devoid of an exogenous polynucleotide encoding the reprogramming factor LIN28A polypeptide.

[0197] According to some embodiments, the combination of one or more reprogramming factors may comprise or be devoid of an exogenous polynucleotide encoding the reprogramming factor MYC.

[0198] According to some embodiments, the method of producing one or more mammalian iPSCs comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, and PRDM14. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, PRDM14 and at least one agent downregulating a transcription factor or its activity, wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, and PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG,and PRDM14 and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, and PRDM14, p53DD or shp53, and JDP2. According to certain exemplary embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, PRDM14 and LIN28A. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, PRDM14 and MYCL. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, LIN28A and MYCL. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL and at least one agent downregulating a transcription factor or its activity wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53 and JDP2. According to some embodiments, the chimeric SOX2 is SOX2-VP160. According to some embodiments, the chimeric SOX2 is SOX2-17. According to any one of the above embodiments, an agent inhibiting p53 is GSE56. According to any one of the above embodiments, an agent inhibiting API is shFOS or shJUN. According to some embodiments, one or more agent inhibiting API and / or one or more agent inhibiting p53 may be used. According to some embodiments, the mammalian somatic cell is a bovine somatic cell. According to some embodiments, the bovine somatic cell are cells of inbredbeef. According to some embodiments, the bovine somatic cell are cells of outbred beef. According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG and SALL4. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and at least one agent downregulating a transcription factor or its activity, wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, and SALL4 and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, and SALL4 and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, and SALL4 and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, and SALL4, p53DD or shp53, and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG and SALL4. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and LIN28A. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and MYCL. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, LIN28A and MYCL. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and at least one agent downregulating a transcription factor or its activity wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof.According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53 and JDP2. According to some embodiments, the chimeric SOX2 is SOX2-VP160. According to some embodiments, the chimeric SOX2 is SOX2-17. According to any one of the above embodiments, an agent inhibiting p53 is GSE56. According to any one of the above embodiments, an agent inhibiting API is shFOS or shJUN. According to some embodiments, one or more agent inhibiting API and / or one or more agent inhibiting p53 may be used. According to some embodiments, the mammalian somatic cell is a bovine somatic cell. According to some embodiments, the bovine somatic cell are cells of inbred beef. According to some embodiments, the bovine somatic cell are cells of outbred beef.

[0199] According to certain exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4 and PRDM14. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, and PRDM14 and at least one agent downregulating a transcription factor or its activity, wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, and PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, and PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4,and PRDM14 and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, and PRDM14, and p53DD or shp53, and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, PRDM14 and LIN28A. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, PRDM14 and MYCL. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, LIN28A and MYCL. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and at least one agent downregulating a transcription factor or its activity wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53 and JDP2. According to some embodiments, the chimeric SOX2 is SOX2-VP160. According to some embodiments, the chimeric SOX2 is SOX2-17. According to any one of the above embodiments, an agent inhibiting p53 is GSE56. According to any one of the above embodiments, an agent inhibiting API is shFOS or shJUN. According to some embodiments, one or more agent inhibiting API and / or one or more agent inhibiting p53 may be used. According to some embodiments, the mammalian somatic cell is a bovine somatic cell. According to some embodiments, the bovine somatic cell are cells of inbred beef. According to some embodiments, the bovinesomatic cell are cells of outbred beef.

[0200] According to certain currently exemplary embodiments, the method of producing one or more mammalian iPSCs comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4 and PRDM14. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14 and at least one agent downregulating a transcription factor or its activity, wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and PRDM14 and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and PRDM14 and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, and PRDM14, and p53DD or shp53, and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14 and LIN28A. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14 and MYCL. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, LIN28A and MYCL. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and at least one agent downregulating a transcription factor or its activity, wherein the transcription factor is selected from p53 transcription factor, AP-1 transcription factor or a part thereof. According to some embodiments, the methodcomprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and JDP2. According to some embodiments, the method comprises introducing a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53 and JDP2. According to some embodiments, the chimeric SOX2 is chimeric SOX2-VP160. According to some embodiments, the chimeric SOX2 is chimeric SOX2-17. According to any one of the above embodiments, an agent inhibiting p53 is GSE56. According to any one of the above embodiments, an agent inhibiting API is shFOS or shJUN. According to some embodiments, one or more agent inhibiting API and / or one or more agent inhibiting p53 may be used. According to some embodiments, the mammalian somatic cell is a bovine somatic cell. According to some embodiments, the bovine somatic cell are cells of inbred beef. According to some embodiments, the bovine somatic cell are cells of outbred beef.

[0201] According to some embodiment, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs), the method comprising introducing into one or more mammalian somatic cells five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, a factor of the LIN28 family, a factor of the MYC family, and an agent downregulating p53 and an agent downregulating AP-1. According to some embodiments, the agent downregulating p53 is p53DD or shp53, and the agent downregulating AP-1 is JDP2 or shFOS or shJUN. According to some embodiment, the present invention provides a method of producing one or more mammalian induced pluripotent stem cells (iPSCs), the method comprising introducing into one or more mammalian somatic cells at least one exogenous polynucleotide encoding five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, a factor of the LIN28 family, a factor of the MYC family, p53DD and JDP2. According to some embodiments, the mammalian cells are bovine cells. According to some embodiments, the chimericS0X2 is chimeric SOX2-VP160. According to some embodiments, the chimeric SOX2 is chimeric SOX2-17. According to some embodiments, the bovine somatic cell are cells of inbred beef. According to some embodiments, the bovine somatic cell are cells of outbred beef.

[0202] According to any one of the aspects and embodiments of the present invention, OCT4 is encoded by a nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 83.

[0203] According to any one of the aspects and embodiments of the present invention, chimeric SOX2 is SOX2-VP160 comprises an amino acid sequence SEQ ID NO: 1.

[0204] According to any one of the aspects and embodiments of the present invention, chimeric SOX2 is S 0X2- 17 is encoded by a nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 90.

[0205] According to any one of the aspects and embodiments of the present invention, KLF4 is encoded by a nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 84.

[0206] According to any one of the aspects and embodiments of the present invention, SALL4 is encoded by a nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 85.

[0207] According to any one of the aspects and embodiments of the present invention, PRDM14 is encoded by a nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 86.

[0208] According to any one of the aspects and embodiments of the present invention, NANOG is encoded by a nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 87.

[0209] According to any one of the aspects and embodiments of the present invention, LIN28A is encoded by a nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 88.

[0210] According to any one of the aspects and embodiments of the present invention, MYCL is encoded by a nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 89.According to any one of the aspects and embodiments of the present invention, p53DD encoded by a nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 81 or 82.

[0211] According to any one of the aspects and embodiments of the present invention, JDP2 is encoded by a nucleic acid comprising the nucleic acid sequence as set forth in SEQ ID NO: 80.

[0212] The present invention provides combinations of different factors. It is clear that all combinations naming the factors and agents inhibiting p53 or API encompass also the combinations of their amino acids or nucleic acids encoding the amino acid sequence as defined herein above. For example, a combination of factors OCT4, chimeric SOX2, KLF4, NANOG and SALL4 encompasses a combination of amino acid sequences encoded by nucleic acid sequences SEQ ID NO: 83 (OCT4), 84 (KLF4), 87 (NANOG), and 85 (SALL4) and an amino acid SEQ ID NO: 1 (SOX2-VP160) or an amino acid sequence encoded by the nucleic acid sequence SEQ ID NO: 90 (SOX2-17). Another explicit example of a combination of factors of nucleic acids encoding said factors comprises a combination of exogenous reprogramming factors comprising OCT4, chimeric SOX2, KLF4, NANOG, SALL4, PRDM14, and (i) LIN28A, (ii) MYCL or (iii) both LIN28A and MYCL, and p53DD or shp53 and JDP2. Such combination encompasses a combination of amino acid sequences encoded by nucleic acid sequences SEQ ID NOs: 83 (OCT4), 84 (KLF4), 87 (NANOG), 85 (SALL4), 86 (PRDM14), 81 or 82 (p53DD), 80 (JDP2), and (i) SEQ ID NO: 88 (LIN28A), (ii) SEQ ID NO: 89 (MYCL) or (iii) both SEQ ID NOs: 88 and 89, and the amino acid SEQ ID NO: 1 (SOX2-VP160) or an amino acid sequence encoded by the nucleic acid sequence SEQ ID NO: 90 (SOX2-17). It is understood that any combination of factors and agents may be formed according to these examples.

[0213] According to any one of the aspects and embodiments, the nucleic acid molecule of the present invention comprises at least one of the sequences selected from SEQ ID NO: 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 and a nucleic acid encoding SEQ ID NO: 1. According to some embodiments, the nucleic acid molecule of the present invention comprises at least one of the sequences selected from SEQ ID NO: 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 90, and a nucleic acid encoding SEQ ID NO: 1. According to someembodiments, the present invention provides a variant of said sequences. The terms “homolog” “variant”, “DNA variant”, “sequence variant” and “polynucleotide variant” are used herein interchangeably and refer to a DNA polynucleotide having at least 70% sequence identity to the parent polynucleotide and encoding the peptide(s) or protein(s) having the same functions and structure as the peptide(s) or protein(s) encoded by the parent polynucleotide. The variant may include mutations such as deletion, addition or substitution such that the mutations do not change the open reading frame and the polynucleotide encodes a peptide or a protein having substantially similar structure and function as a peptide or a protein encoded by the parent polynucleotide. According to some embodiments, the variants are conservative variants. The term “conservative variants" as used herein refers to variants in which a change of one or more nucleotides in a given codon position results in no alteration in the amino acid encoded at that position. Thus, the peptide or the protein encoded by the conservative variants has 100% sequence identity to the peptide or the protein encoded by the parent polynucleotide. According to some embodiments, the variant is a non-conservative variant encoding to a peptide or a protein being a conservative analog of the peptide of the protein encoded by the parent polynucleotide. According to some embodiments, the variant has at least 75%, at least 80% at least 85%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to the parent polynucleotide.

[0214] The cell types and the origin of the reprograming proteins are as described hereinabove in any one of the aspects and embodiments of the invention.

[0215] According to certain embodiments, the produced one or more iPSCs comprise the encoded five or more reprograming factors. According to further embodiments, the five or more reprograming factors are expressed in the cells for at least five days.

[0216] According to another aspect, the present invention provides a plurality of mammalian iPSCs produced by the methods of the present invention. According to some embodiments, the mammalian somatic cell is a somatic cell of a mammal selected from selected from a livestock animals (including bovines, porcine, etc.), humans, primates, companion animals (e.g., canines, felines, etc.) and rodents. According to some embodiments, the mammalian somatic cell is a somatic cell of a livestock animal. According to some embodiments, the mammalian somatic cell is a bovine somatic cell.According to some embodiments, the present invention provides a plurality of mammalian iPSCs produced by a method comprising introducing into one or more mammalian somatic cells five or more reprogramming factor proteins or at least one exogenous polynucleotide encoding the five or more reprogramming factors, wherein the five reprogramming factor proteins comprise OCT4, chimeric SOX2 and a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM. According to certain embodiments, the plurality of bovine iPSCs endogenously express at least OCT4 and SOX2. According to further embodiments, the plurality of mammalian iPSCs further express endogenous NANOG. According to certain embodiments, the plurality of mammalian iPSCs is able to self-renew, proliferate and differentiate for at least 20 passages. According to certain embodiments, the plurality of mammalian iPSCs express the endogenous factors OCT, SOX2 and NANOG and are able to self-renew, proliferate and differentiate for at least 20 passages. According to certain embodiments, the plurality of mammalian iPSCs express additional reprograming factors selected from the group consisting of a factor of the LIN28 family, a factor of the MYC family, a p53 downregulating agent, an AP-1 or a part thereof downregulating agent, and any combination thereof. Each possibility represents a separate embodiment of the present invention. According to some embodiments, the mammalian somatic cell is a bovine somatic cell.

[0217] According to some embodiments, the mammalian iPSC express an endogenous marker selected from LIN28A, OCT4, SALL4, SOX2, UTF1, ZFP42, and a combination thereof. According to some embodiments, the mammalian iPSC express a combination of endogenous markers selected LIN28A, PRDM14, OCT4, and SALL4. According to some embodiments, the mammalian iPSC are bovine iPSC.

[0218] According to any one of the above embodiments, the induced pluripotent cells of the present invention can propagate indefinitely in culture.

[0219] According to certain embodiments, the plurality of mammalian iPSCs of the present invention are for use in cultured food products, cosmetics or medicine.

[0220] According to certain embodiments, the plurality of a life stock animal iPSCs of the present invention is for use in producing cultured food product. According to someembodiments, the life stock animal iPSCs are bovine iPSCs. According to further embodiments, the cultured food product is cultured meat.

[0221] According to some embodiments, the present invention provides a method of producing a cultured food product the method comprises producing a plurality of a life stock animal iPSCs as described in any one of the above aspects and embodiments, culturing the produced life stock animal iPSCs under conditions enabling propagation and differentiation of the produced iPSC into somatic a life stock animal cells, thereby producing one or more a life stock animal somatic cells and preparing a cultured food product. According to some embodiments, the life stock animal cells are bovine cells. According to some embodiments, the bovine cells are cells of inbred beef.

[0222] According to certain embodiments, the present invention provides a method for producing one or more mammalian somatic cells, the method comprising the steps of: 1) producing one or more mammalian iPSCs as described in any one of the aspects and embodiments of the present invention; and

[0223] 2) culturing the produced mammalian iPSCs under conditions enabling propagation and differentiation of the produced iPSC, thereby producing one or more mammalian somatic cells.

[0224] According to some embodiments, the mammalian cell is a bovine cell, (either somatic of iPSC)

[0225] According to certain embodiments, the present invention provides a method for producing one or more mammalian somatic cells, the method comprising the steps of: 1) producing one or more mammalian iPSCs by the following steps:

[0226] a) introducing into one or more mammalian somatic cells at least one exogenous polynucleotide encoding five or more reprogramming factors, or

[0227] b) introducing into one or more mammalian somatic cells five or more reprogramming factor proteins;

[0228] wherein the five reprogramming factor proteins comprise OCT4, chimeric SOX2 and a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family, thereby producing one or more mammalian iPSCs; and2) culturing the produced mammalian iPSCs under conditions enabling propagation and differentiation of the produced iPSC, thereby producing one or more mammalian somatic cells. According to some embodiments, the mammalian cell is a bovine cell, (either somatic of iPSC).

[0229] According to certain embodiments, the present invention provides a method for producing one or more mammalian somatic cells, the method comprising the steps of: 1) producing one or more mammalian iPSCs by the following steps:

[0230] a) introducing into one or more mammalian somatic cells at least one exogenous polynucleotide encoding five or more reprogramming factors, or

[0231] b) introducing into one or more mammalian somatic cells five or more reprogramming factor proteins;

[0232] wherein the five reprogramming factor proteins comprise OCT4, chimeric SOX2 and a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family; 2) introducing into one or more bovine somatic cells one or more additional reprogramming proteins or at least one exogenous polynucleotide encoding the five or more reprogramming factors;

[0233] wherein the additional reprogramming proteins comprise a factor of the LIN28 family, a factor of the MYC family, a factor of the p53DD family, JDP2, and any combination thereof, thereby producing one or more bovine iPSCs; and

[0234] 3) culturing the produced mammalian iPSCs under conditions enabling propagation and differentiation of the produced iPSC, thereby producing one or more bovine somatic cells. According to some embodiments, the mammalian cell is a bovine cell (either somatic of iPSC).

[0235] According to certain embodiments, culturing the iPSCs produced by the methods of the invention comprises culturing said iPSC under 2D or 3D culture conditions. Any 2D and 3D culture conditions known to be suitable for culturing iPSCs can be used according to the teachings of the present invention.

[0236] According to any one of the aspects and embodiments of the present invention, theproduced one or more bovine somatic cells is selected from the group consisting of stromal cells, skeletal muscle cells, adipocytes, stromal cells, endothelial cell, and any combination thereof. Each possibility represents a separate embodiment of the present invention.

[0237] The present invention further provides mammalian somatic cell produced by the methods of the invention. The present invention further provides bovine somatic cell produced by the methods of the invention.

[0238] According to additional certain aspects, the present invention provides a chimeric SOX2-VP160 polypeptide comprising an amino acid sequence at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 90% homologous to, or identical, to the amino acid sequence set forth in SEQ ID NO:1. According to additional certain aspects, the present invention provides a chimeric SOX2-VP160 polypeptide consisting of an amino acid sequence at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 90% homologous to, or identical, to the amino acid sequence set forth in SEQ ID NO:1. According to additional certain aspects, the present invention provides a chimeric SOX2-VP160 polypeptide consisting of an amino acid sequence SEQ ID NO:1. According to additional certain aspects, the present invention provides a chimeric SOX2-VP160 polypeptide comprising an amino acid sequence at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 90%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 90% homologous to, or identical, to the amino acid sequence set forth in SEQ ID NO: 1 for use in reprogramming mammalian-derived cell (e.g. bovine-derived cell) to produce mammalian induced pluripotent stem cell (iPSC). Each possibility represents a separate embodiment of the present invention. According to some embodiments, the SOX2-VP160 polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO:1. According to some embodiments, the present invention provides a method to producemammalian induced pluripotent stem cell (iPSC) from a mammalian somatic cell the method comprises introducing into a mammalian somatic cell the SOX2-VP160 polypeptide or a nucleic acid encoding said SOX2-VP160 polypeptide.

[0239] According to yet further aspects, the present invention provides an induced mammalian pluripotent stem cell (iPSC), which is obtainable by the methods of the present invention. According to some embodiments,, the present invention provides an induced mammalian pluripotent stem cell (iPSC), which is obtainable by a method comprising introducing into a bovine somatic cell a combination of five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, chimeric SOX2, and a factor of the KLF family, and at least two additional reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family or at least one exogenous polynucleotide encoding the combination of five or more reprogramming factors. According to some embodiments, the mammalian cell is a bovine cell.

[0240] According to certain embodiments, the iPSC is obtainable by further introducing additional reprogramming factor proteins selected from the group consisting of a factor of the LIN28 family and a factor of the MYC family, and at least one agent downregulating the transcription factor p53, including, but not limited to, dominantnegative mutant of p53 (p53DD), and at least one agent downregulating the activity of a transcription factor of the AP-1 or a part thereof, including, but not limited to, JDP2, a dominant negative modulator of c-Fos and c-Jun, and any combination thereof or introducing at least one exogenous polynucleotide encoding the additional reprogramming factors and an agent downregulating the transcription factor(s).

[0241] According to further certain aspects, the present invention provides a combination comprising five or more reprogramming factors wherein the combination comprises OCT4, chimeric SOX2, and a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family.

[0242] According to certain embodiments, the combination further comprises one or more additional reprogramming factor, wherein the one or more additional reprograming factor is selected from the group consisting of a factor of the LIN28 family and a factor of theMYC family. According to yet additional embodiments, the combination further comprises an agent downregulating AP-1 or a part thereof and / or an agent downregulating p53. The following examples are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.

[0243] According to other embodiments, the present invention provides a set of nucleic acids comprising a plurality of nucleic acids encoding the combination of the five or more reprogramming factors. According to other embodiments, a set of nucleic acids further comprises one or more nucleic acids encoding the additional reprogramming factor(s). According to other embodiments, a set of nucleic acids further comprises one or more nucleic acids encoding an agent downregulating AP-1 or a part thereof and / or an agent downregulating p53. According to some embodiments, the present invention provides a single nucleic acid encoding the five or more reprogramming factors. According to some embodiments, the present invention provides a single nucleic acid encoding the five reprogramming factors and the additional reprogramming factor(s). According to some embodiments, the present invention provides a single nucleic acid encoding: (i)the five reprogramming factors, (ii) the additional reprogramming factor(s), and (iii) an agent downregulating AP-1 or a part thereof and / or an agent downregulating p53. The reprogramming factor(s), the additional reprogramming factor(s) and the agent downregulating p53 and / or AP-1 or a part thereof are as described in any one of the above aspects and embodiments.

[0244] Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.

[0245] EXAMPLES

[0246] Material and Methods

[0247] Cell Lines

[0248] Seven primary bovine lines: Bovine Embryonic Fibroblasts (BEF, Aleph Farms),Bovine Embryonic Myoblasts (BEM, Aleph Farms), Adipose tissue-derived bovine Mesenchymal Stem Cells (bMSC, Aleph Farms), Bovine satellite cells (Bsh3, Aleph Farms), Bovine Endothelial Progenitor Cells (bEPCs, Aleph Farms), Bovine cord lining cells (BCL2A, Aleph Farms), Bovine Dermal Fibroblasts (BDF, ScienCell), and bovine fibroblast-like cells (mesenchymal (stromal) cells differentiated from bovine embryonic stem cell, Aleph Farms) obtained from an Angus bred cow were used in this study. Bovine blastocyst-derived ESCs (bESC, Aleph Farms) were used as PSC control. Human embryonic kidney cells (HEK293) were used for lenti- or retro- viral production. All cells were grown at 37°C and 6% CO2. The specific medium composition required for cell growth of each cell type are summarized in Table 1.

[0249] Table 1: The various bovine primary cells and their culture conditions

[0250] Cell Line Growth Medium and conditions

[0251] Bovine Embryonic Standard growth media - DMEM (Gibco™, #11965092) Fibroblasts (BEF) containing 10% FBS (BI, #04-001-lA), 1% L-glutamine (Sigma, #G7513) and 1% penicillin- streptomycin (Sigma, #P4333)

[0252] Bovine Embryonic Myoblasts Enriched growth media - DMEM (Gibco™, #11965092) (BEM) containing 20% FBS (BI, #04-001-lA), 1% L-glutamine (Sigma, #G7513) and 1% penicillin- streptomycin (Sigma, #P4333)

[0253] Adipose tissue derived Standard growth media - DMEM (Gibco™, #11965092) bovine Mesenchymal Stem containing 10% FBS (BI, #04-001-lA), 1% L-glutamine Cells (bMSC) (Sigma, #G7513) and 1% penicillin- streptomycin (Sigma,

[0254] #P4333)

[0255] Bovine satellite cells (Bsh3) AmnioGrow Medium (A GM) (biowest, #AGM) Bovine Endothelial EGM-2MV Microvascular Endothelial Cell Growth Progenitor Cells (bEPCs) Medium-2 BulletKit (Lonza, #CC-3202)

[0256] Or

[0257] EndoGo (BI, #05-400-1 A) +

[0258] Supplement Mix (BI, #05-410-1) + 10% FBS (BI, #04-001- 1A)

[0259] Bovine cord lining cells Standard growth media - DMEM (Gibco™, #11965092) (BCL2A) containing 10% FBS (BI, #04-001-lA), 1% L-glutamine (Sigma, #G7513) and 1% penicillin- streptomycin (Sigma, #P4333)

[0260] Angus fibroblast-like cells Fibroblasts Medium-2 (FM-2) (ScienCell, #2331) - basal medium, 5% FBS (ScienCell, #0025), 1% fibroblast growth supplement-2 (ScienCell, #2382), and 1% antibiotic solution

[0261]

[0262] (P / S, ScienCell, #0503)Cell Line Growth Medium and conditions

[0263] Bovine Embryonic Stem bESC medium - mTeSRl (STEMCELL, #85850) + 2.5qM Cells (bESC) IWR-1 (Focus Biomolecules, #10-5081); Seeded on mouse feeder-containing plate

[0264] Bovine Dermal Fibroblasts Fibroblasts Medium-2 (FM-2) (ScienCell, #2331) - basal (BDF) (ScienCell Cat B2300) medium, 5% FBS (ScienCell, #0025), 1% fibroblast growth supplement-2 (ScienCell, #2382), and 1% antibiotic solution

[0265]

[0266] (P / S, ScienCell, #0503)

[0267] Molecular Cloning

[0268] The cloning of the various reprogramming factors into Dox-inducible FUW-TetO, Dox-inducible pCW57.1, FUW, pMX retroviral vector and pCXLE (Addgene) were generated by cloning the open reading frame of each factor using NEBNext® Ultra™ II Q5® Master Mix (NEB) and a specific set of primers flanking its coding region (advise SEQ ID NOs: 2-79). The relevant PCR product was restricted with EcoRI or Mfel and inserted into each of the above plasmids followed by sanger sequencing. Alternatively, genes were synthesized by Twist (hKLF5, bOCT4, bSOX2, bKLF4, bMYC, bSALL4, bCDHl, bNANOG, bLIN28, bSOXll, bNMYC, bKLF2, bGATA3, bTFAP2C) cloned into the various vectors or obtained directly from Addgene (hOCT4, hSOX2, hKLF4, hMYC, hOSKM, hOSKM, hSOX2-17, mCebpa). Bovine shRNA vectors were cloned by annealing specific oligos (advise SEQ ID NOs: 2-79), that were later restricted by Agel and EcoRI and inserted into pLKO.l vector (Addgene).

[0269] Quantitative PCR (qPCR)

[0270] For analysis of mRNA expression using qPCR, total RNA was isolated using the Macherey-Nagel kit (Ornat). 500-1000ng of total RNA was reverse transcribed using LunaScript® RT SuperMix (NEB). Quantitative PCR analysis was performed in triplicate and two technical duplicates for each replicate using 1 / 100 of the reverse transcription reaction in a StepOnePlus (Applied Biosystems) with Luna® Universal qPCR Master Mix (NEB). Specific qPCR primers flanking an intron were designed for the different genes (SEQ ID NOs: 2-79). All qRT-PCR experiments were normalized to the expression of the housekeeping control gene GAPDH and presented as a mean ± standard deviation of three replicates.biPSC reprogramming via lentiviral or retroviral infections

[0271] For infection, replication-incompetent lentiviruses containing a total of 2pg DNA of the various reprogramming factors with the indicated ratio (Table 3) were packaged with a total of 2pg DNA of lentiviral packaging vectors (Ipg psPAX2 and Ipg pDGM.2) in 1.5M HEK293 cells per reaction in a 6-well. For retroviral infection, PSVG (Addgene) packaging vector was used in a ratio of 1:1 with the relevant expression vectors. PEI (Img / mL, Sigma) was used as a transfection reagent. Alternatively, FuGene-HD (Promega) was used as a transfection reagent, with a total of Ipg DNA of the various reprogramming factors packaged with a total of Ipg DNA of lentiviral packaging vectors (0.5pg psPAX2 and 0.5pg pDGM.2). Supernatant was collected 48 hours posttransfection, supplemented with 8pg / ml of polybrene, and filtered through a 0.45pm filter. Filtered supernatant was used to infect cells, (20K / 40K / 50K / 60K / 80K / 100K cells): BEFs, BEMs, bMSC, Bsh3, bEPC or BCL2A, that were seeded onto 6-well plates coated with 0.2% gelatin 24h pre-infection.

[0272] For dox-inducible gene expression, infected cells were initially transduced with lentiviral vector encoding for M2rtTA-2A-puromycin, and subsequently selected with 2 pg / mL puromycin for 3-5 days. For reprogramming with constitutively active vectors, freshly isolated cells were used (up to passage 2). Twelve hours following infection, medium was replaced with basic reprogramming medium (BRM) consisting of fresh DMEM containing 10% FBS, 1% L-glutamine and 1% penicillin-streptomycin. For inducible expression, 2pg / ml doxycycline (dox) was added to the medium. The reprogramming medium was changed every other day. After 7 days in BRM with dox, the medium was replaced with 50% BRM and 50% bESC medium (mTeSR supplemented with IWR-1 (2.5pM)) with dox, followed by 7 days in bESC medium with dox. Following 21 days of dox addition, dox was removed from the plates for 7 days and cells were trypsinized and seeded on mouse feeder-containing plate to screen for the emergence of any iPSC colonies.

[0273] Various small molecules and inhibitors were also added to the reprogramming media and screened for boasting the reprogramming process of BEFs, BEMs and bMSCs, as described in Table 2 hereinbelow.Table 2: List of the small molecules used in this study to promote reprogramming Molecule name Pathway Concentration XAV939 2 pM

[0274] Wnt inhibitor

[0275] IWR-1 2.5 pM

[0276] CHIR99021 Wnt signaling activators 2, 10 pM

[0277] A83-O1 0.5-20 pM

[0278] TGFb inhibitors

[0279] SB43125 1 pM

[0280] PD032501 10 pM

[0281] MAPK signaling inhibitors

[0282] PD98059 50 pM

[0283] TSA 10 nM

[0284] Histone deacetylase inhibitors

[0285] VPA 800 pM

[0286] 5-AZA DNA methylation inhibitors 500 nM

[0287] DOTILi 10 pM

[0288] Histone methyltransferase inhibitor

[0289] A366 3, 6 pM

[0290] Ascorbic acid Histone methylation modulator 1.5-25 pg / mL

[0291] JBSNF NNMT inhibitor 1 pM

[0292] Y-27632 ROCK inhibitor 5, 10 pM

[0293] GM6001 Collagenase inhibitor 100 pM

[0294] JNK-IN-8 JNK 1 / 2 / 3 inhibitor 1 pM

[0295] JAKi JAK inhibitor 1 pM

[0296]

[0297] bFGF FGF2 growth factor 4 ng / ml

[0298] biPSC reprogramming via mRNA transfection

[0299] 50K / 80K / 100K / 150K cells of BEF, BEM, bMSC, and Bsh3 cells were seeded on Matrigel coated 6-well plates containing either bESC medium or NutriStem (BI). Subsequently, cells were transfected 4-6 times every 24 hours with hOCT4, hSOX2, hKLF4, hMYC, hLIN28 and hNANOG (OSKMNL) mRNA using the StemRNA 3rd Gen Reprogramming Kit (ReproCell) according to the manufacturer’s instructions. Cells were examined every day for morphology change and emergence of colonies. For Bsh3 cells, initial medium was bESC, NutriStem or AGM medium, and when starting with AGM, medium was exchanged after 2 days to either bESC medium or Nutristem.

[0300] Generation of non-integrating episomal-derived biPSCs

[0301] Episomal vectors: pCXLE-hOCT4-shp53, pCXLE-hSOX2-17-hKLF4, pCXLE-hL-MYC / hLIN28A, and pCXWB-EBNAl were originally described in (Okita et al.

[0302] 2011, Nat Methods, 8(5):409-12; Okita et al. 2012, Stem Cells., 31(3):458-66; MacCarthy et al. 2024, Cell Stem Cell., 4;31(1): 127-147) and were obtained from Addgene. pCXLE-hSOX2-VP160, pCXLE-hKLF4, pCXLE-bNANOG, pCXLE-hSALL4 and pCXLE-mPRDM14 vectors were generated by subcloning the open reading frame of either hSOX2-VP160 (the VP160 fragment was synthesized by GenScript), bNANOG, hSALL4 or mPRDM14 into pCXLE vector using EcoRI or Mfel enzymes. For electroporation, fibroblasts were trypsinized and 5xl05cells were resuspended in 100 pL of R buffer (Life Technologies, Carlsbad, CA, USA). Subsequently, 0.7pg / 100pL of each of the episomal plasmids (pCXLE-hOCT4-shp53, pCXLE-hSOX2-17-hKLF4, pCXLE-hL-MYC / hLIN28A, pCXLE-bNANOG, pCXLE-hSALL4 and pCXLE-mPRDM14) with 0.8pg / 100 pL of pCXWB-EBNAl episomal plasmid were added to the cell suspension. Alternatively, the episomal plasmids pCXLE-hOCT4-shp53, pCXLE-hSOX2-VP160, pCXLE-hKLF4, pCXLE-hL-MYC / hLIN28A, pCXLE-bNANOG, pCXLE-hSALL4 and pCXLE-mPRDM14 (0.9pg / 100, 0.6pg / 100, 0.5pg / 100, 0.9pg / 100, 0.4pg / 100, 0.5pg / 100, 0.4pg / 100 accordingly) with 0.8pg / 100 pL of pCXWB-EBNAl episomal plasmid were added to the cell suspension. Electroporation was carried out with the NEON transfection system (Life Technologies; 1,650V, 10ms, 3 pulses) according to the manufacturer’s instructions. Subsequently, cells were seeded onto 6-well plates coated with mouse feeder cells, containing Fibroblasts Medium-2 (FM-2, ScienCell), consisting of 500mL of basal medium, 25mL of FBS (ScienCell), 5mL of fibroblast growth supplement-2 (ScienCell), and 5mL of antibiotic solution (P / S, ScienCell). The fibroblasts were cultured in FM-2 for 5 days, then the medium was exchanged to 50% FM-2 and 50% bESC medium for 2 days, and then the medium was exchanged once again for 100% bESC medium for another 8 days.

[0303] Following 8 days, plates were screened for bovine iPSC colonies, then trypsinized and plated on a new mouse feeder-containing plate. biPSCs were passaged several times until stable proliferative biPSC colonies emerged.

[0304] Table 3 describes the different reprogramming factors combinations and their ratios, used in viral infections, mRNA transfections and episomal vectors electroporation.

[0305] Table 3: List of reprogramming factors combinations and ratios that were unsuccessful in producing bovine iPSCs

[0306] Factors combination - Ratio Method

[0307] 1 hOCT4 - 3, hSOX2 - 3, hKLF4 - 3, hMYC - 1 lentiviral infection

[0308]

[0309] Factors combination - Ratio Method hOCT4 - 1, hSOX2 - 1, hKLF4 - 1, hMYC - 1, hNANOG lentiviral infection - 0.5, hLIN28 - 0.5, hSALL4 - 1

[0310] hOCT4 - 1, hSOX2 - 1, hKLF4 - 1, hMYC - 1, hNANOG lentiviral infection - 1, hLIN28 - 1, hSALL4 - 1, mCebpa - 1, bNMYC - 1

[0311] hOCT4 - 1, hSOX2 - 1, hKLF4 - 1, hMYC - 1, hNANOG lentiviral infection - 1, hSALL4 - 1

[0312] hOCT4 - 1, hSOX2 - 1, hKLF4 - 1, hMYC - 1, hNANOG lentiviral infection - 1, hSALL4 - 1, hESRRB - 1

[0313] hOCT4 - 1, hSOX2 - 1, hMYC - 1, hNANOG - 1, hLIN28 lentiviral infection - 1, hSALL4 - 1, hGATA3 - 1, bCDHl - 1

[0314] hSOX2 - 1, hNANOG - 1, hLIN28 - 1, hSALL4 - 1, lentiviral infection hTFAP2C - 1, bCDHl - 1

[0315] hKLF4 - 1, hMYC - 1, bKLF4 - 1, bMYC - 1, bNMYC - 1 lentiviral infection hOCT4 - 1, hSOX2 - 1, hKLF4 - 1, hMYC - 1, hNANOG lentiviral infection - 1, bLIN28 - 1, bSALL4 - 1, bTFAP2C - 1, bCDHl - 1,

[0316] bGATA3 - 1, bKLF2 - 1, bNMYC - 1, bSOXll - 1

[0317] hOCT4 - 1, hSOX2 - 1, hMYC - 1, hNANOG - 1, hLIN28 lentiviral infection - 1, hSALL4 - 1, hHRAS - 1, hKLF5 - 1, mPrdml4 - 1

[0318] bOCT4 - 3, bSOX2 - 3, bKLF4 - 3, bMYC - 1 lentiviral infection mCebpa - 1, bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - lentiviral infection 1, bNANOG - 1, bLIN28 - 1, bSALL4 - 1

[0319] bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, bNANOG lentiviral infection - 1, bLIN28 - 1

[0320] hKLF5 - 1, bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, lentiviral infection bNANOG - 1, bLIN28 - 1, bSALL4 - 1, bTFAP2C - 1,

[0321] bCDHl - 1, bGATA3 - 1, bKLF2 - 1

[0322] hKDMla - 1, mKdmla - 1, mKdm4d - 1, bOCT4 - 1, lentiviral infection bSOX2 - 1, bKLF4 - 1, bMYC - 1, bNANOG - 1, bLIN28

[0323] - 1

[0324] bNMYC - 1, bSOXll - 1 lentiviral infection hKLF5 - 1, hEOMES - 1, mCebpa - 1, bOCT4 - 1, bSOX2 lentiviral infection - 1, bKLF4 - 1, bMYC - 1, bNANOG - 1, bLIN28 - 1,

[0325] bSALL4 - 1, bNMYC - 1, bSOXll - 1

[0326] bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, bNANOG lentiviral infection - 1, bLIN28 - 1, bSALL4 - 1, bTFAP2C - 1, bCDHl - 1,

[0327] bSOXll - 1

[0328] hKLF5 - 1, bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, lentiviral infection bNANOG - 1, bLIN28 - 1, bSALL4 - 1, bCDHl - 1,

[0329] bNMYC - 1, bSOXll - 1

[0330] bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, bNANOG lentiviral infection - 1, bLIN28 - 1, bSALL4 - 1

[0331] hKLF5 - 1, hEOMES - 1, mCebpa - 1, bOCT4 - 1, bSOX2 lentiviral infection - 1, bKLF4 - 1, bMYC - 1, bNANOG - 1, bLIN28 - 1,

[0332]

[0333] bSALL4 - 1, bCDHl - 1, bNMYC - 1, bSOXll - 1Factors combination - Ratio Method hKLF5 - 1, hEOMES - 1, hSOXlO - 1, mCebpa - 1, bOCT4 lentiviral infection - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, bNANOG - 1,

[0334] bLIN28 - 1, bSALL4 - 1, bCDHl - 1, bNMYC - 1,

[0335] bSOXll - 1

[0336] hOSKM cass. - 7, hMYC - 1, hNANOG - 1, hSALL4 - 1 lentiviral infection hOSKM const, cass. - 9, hMYC - 1 lentiviral infection hKLF5 - 1.5, bOCT4 - 3, bSOX2 - 3, bKLF4 - 1.5, bMYC lentiviral infection - 1

[0337] hKLF5 - 1, bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, lentiviral infection bNANOG - 1, bLIN28 - 1, bSALL4 - 1, bTFAP2C - 1,

[0338] bCDHl - 1, bGATA3 - 1

[0339] hKLF5 - 1, bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, lentiviral infection bNANOG - 1, bLIN28 - 1

[0340] hKLF5 - 1, bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, lentiviral infection bNANOG - 1, bLIN28 - 1, bSALL4 - 1, bCDHl - 1,

[0341] bGATA3 - 1

[0342] bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, bNMYC - lentiviral infection 1, bSOXll - 1

[0343] bMYC - 1, bTFAP2C - 1, bCDHl - 1, bNMYC - 1 lentiviral infection bMYC - 1, bLIN28 - 1, bSALL4 - 1, bTFAP2C - 1, bCDHl lentiviral infection - 1, bNMYC - 1

[0344] hOCT4 - 3, hSOX2 - 3, hKLF4 - 2, hMYC - 2, hKLF5 - 4, lentiviral infection bOCT4 - 8, bSOX2 - 8, bKLF4 - 2, bMYC - 2, bNANOG

[0345] - 6, bLIN28 - 3, bSALL4 - 7, bTFAP2C - 1, bCDHl - 9,

[0346] bNMYC - 2, bSOXll - 2

[0347] hKLF5 - 1, bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, lentiviral infection bSOXll - 1

[0348] bOCT4 - 1, bSOX2 - 1, bKLF4 - 1, bMYC - 1, bNANOG lentiviral infection - 1, bLIN28 - 1, bSALL4 - 1, bTFAP2C - 1, bCDHl - 1,

[0349] bGATA3 - 1, bKLF2 - 1, bNMYC - 1, bSOXll - 1

[0350] hOSKM cass. - 8, hNANOG - 1, hLIN28 - 1, lentiviral infection hOCT4 - 1, hSOX2 - 1, hKLF4 - 1, hMYC - 1, hNANOG lentiviral infection - 1, hKDMla - 1, hEOMES - 1, mCebpa - 1, bSOXll - 1

[0351] hKLF4 - 2, hMYC - 1, hNANOG - 1, hLIN28 - 1, hSALL4 lentiviral infection - 2, hHRAS - 1, mPrdml4 - 2

[0352] hOCT4 - 3.5, hSOX2 - 3.5, hKLF4 - 2, hMYC - 1, hLIN28 lentiviral infection - 2, hSALL4 - 8

[0353] hOCT4 - 3.5, hSOX2 - 3.5, hKLF4 - 2, hMYC - 1, lentiviral infection hNANOG - 5, hHRAS - 2, mPrdml4 - 3

[0354] hSALL4 - 1, hTFAP2C - 1, hHRAS - 1, hKLF5 - 1, lentiviral infection hEOMES - 1, hREXl - 1, mPrdml4 - 1, mDnmt3a - 1,

[0355] mDnmt3b - 1

[0356] hOCT4 - 1, hSOX2-17 (chimeric) - 1, hKLF4 - 1, hMYC - lentiviral infection

[0357]

[0358] 1, hNANOG - 0.5, hLIN28 - 0.5Factors combination - Ratio Method hOCT4 - 1, hSOX2-17 (mut) - 1, hKLF4 - 1, hMYC - 1, lentiviral infection hNANOG - 0.5, hLIN28 - 0.5

[0359] hKLF5 - 3, bOCT4 - 3, bSOX2 - 3, bMYC - 1 lentiviral infection hOCT4 - 5, hKLF4 - 4, hMYC - 1, hNANOG - 2.5, lentiviral infection hSOX2-17 - 5, mPrdml4 - 2.5

[0360] hOCT4 - 1, hSOX2 - 1, hKLF4 - 1, hMYC - 1, hNANOG lentiviral infection - 1, mPrdml4 - 1

[0361] hOCT4 - 1, hSOX2 - 1, hMYC - 1, hNANOG - 1, hSALL4 lentiviral infection - 1, hHRAS - 1, hKLF5 - 1, mPrdml4 - 1 (Cells were firstly infected with hOCT4+hSOX2, and a week after were infected again with the rest of the factors) hOCT4 - 5, hKLF4 - 2, hMYC - 1, hNANOG - 2, hSALL4 Lentiviral + shRNA - 3, hSOX2-17 - 5, mPrdml4 - 2

[0362] hOCT4 - 5, hKLF4 - 3, hMYC - 1, hNANOG - 2, hSOX2- Lentiviral + shRNA 17 - 5, mDnmt3b - 4

[0363] hOCT4 - 1, hSOX2 - 1, hKLF4 - 1, hMYC - 1, hNANOG Lentiviral + shRNA - 0.5, hLIN28 - 0.5, hSALL4 - 1

[0364] electroporation: hOCT4 - 1, hSOX2-KLF4 - 1, hMYCL- hLIN28A - 1, hNANOG - 1, hSALL4 - 1, rnPRDM - 1

[0365] + electroporation bOCT4 - 1.5, bSOX2-KLF4 - 1.5, bCMYC - 0.5, shRNA + bNANOG - 1

[0366] electroporation hOCT4 - 1, hSOX2-KLF4 - 1, hMYCL-LIN28A - 1, Electroporation bNANOG - 0.5, hSALL4 - 1, PLKO.l shP53-2 - 0.5

[0367] hOCT4 - 1, hSOX2-KLF4 - 1, hMYCL-LIN28A - 1, Electroporation bNANOG - 0.5, hSALL4 - 1, mPRDM - 1, PLKO.l shP53- 2 - 0.5

[0368] hMYC - 2, hSALL4 - 8, hHRAS - 5, mKDM4A - 5 Lentiviral + mRNA hMYC - 1, hSALL4 - 1, hHRAS - 1, hKDMIA - 1, Lentiviral + mRNA mKDM4D - 1

[0369] hSALL4 - 1, hTFAP2C - 1, hREXl - 1, mPRDM14 - 1 Lentiviral + mRNA hEOMES - 1, mCEBPA - 1 Lentiviral + mRNA mDNMT3A - 1, mDNMT3B - 1 Lentiviral + mRNA hOCT4 - 1, hSOX2-17 (or SOX2-VP160) - 1, KLF4, Electroporation

[0370]

[0371] hMYCL-LIN28A - 0.9, bNANOG - 0.6, hSALL4 - 0.9Table 4: List of reprogramming factors combinations and ratios that were successful in producing bovine iPSCs

[0372] Factors combination - Ratio Method Cells in which bovine iPSCs were obtained

[0373] 1 hOCT4 - 1, hSOX2-17-KLF4 - 1, Electroporation BDF and fibroblasthMYCL-LIN28A - 1, bNANOG - 1, mPRDM14 - like cells

[0374] 1, hSALL4 - 1

[0375] 2 hOCT4 - 0.9, hSOX2-VP160 - 0.6, hKLF4 - 0.5, Electroporation fibroblast-like cells hMYCL-LIN28A - 0.9, bNANOG - 0.4,

[0376] mPRDM14 - 0.4, hSALL4 - 0.5

[0377] 3 hOCT4 - 1, hSOX2-VP160-KLF4 - 1, Electroporation fibroblast-like cells hMYCL-LIN28A - 1, bNANOG - 1,

[0378] mPRDM14 - 1, hSALL4 - 1

[0379] 4 hOCT4 - 0.9, hSOX2-VP160-KLF4 - 0.9, Electroporation fibroblast-like cells bNANOG - 0.8, mPRDM14 - 0.8, hSALL4 - 0.8

[0380] 5 hOCT4 - 1.4, hSOX2-17-KLF4 - 1.4, Electroporation fibroblast-like cells bNANOG - 0.7, hSALL4 - 0.9

[0381] 6 hOCT4 - 0.8, hSOX2-17 (or SOX2-VP160)- KLF4 Electroporation bovine embryonic - 1.2, hMYCL-LIN28A - 0.7, bNANOG - 0.4, myoblasts hSALL4 - 0.7, p53DD - 0.6

[0382] 7 hOCT4 - 0.8, SOX2-17 (or SOX2-VP160)-KLF4 Electroporation bovine embryonic - 1.2, hMYCL-LIN28A - 0.7, bNANOG - 0.6, myoblasts hSALL4 - 0.7, p53DD-hJDP2 - 0.6

[0383] 8 hOCT4 - 0.7, SOX2-17 (or SOX2-VP160)-KLF4 Electroporation bovine embryonic - 1.1, hMYCL-LIN28A - 0.6, bNANOG - 0.4, myoblasts / hSALL4 - 0.7, p53DD-hJDP2 - 0.5, hPRDM14 - bovine embryonic 0.4 fibroblasts /

[0384]

[0385] fibroblast-like cells

[0386] Immunostaining of PFA-fixated cells - for iPSC markers

[0387] Cells were fixed in 4% paraformaldehyde (in PBS) for 20 minutes, then rinsed 3 times with PBS and blocked for 1 hour with PBS containing 0.1% triton X-100 and 5% FBS. The cells were incubated overnight with primary antibodies (1:200 dilution) in 4°C.

[0388] The antibodies used in this study are: anti-SOX2 (Abeam) and anti-TRA-1-60 (Abeam), anti-OCT4 (Abeam) diluted in PBS containing 0.1% triton X-100 and 1% FBS. The next day, the cells were washed 3 times and incubated for 1 hour with relevant (Alexa) secondary antibody in PBS containing 0.1% triton X-100 and 1% FBS (1:500 dilution).DAPI was added 10 minutes before the end of incubation. Negative control included incubation with secondary antibody without primary.

[0389] Flow Cytometry

[0390] Flow cytometry was used to assess the efficiency of lentiviral and episomal vectors infections. Cells were washed with PBS, trypsinized and filtered through mesh paper. Flow cytometry analysis for GFP or tdTomato-positive cells was performed on a Beckman Coulter (Gallios) flow cytometer using the Kaluza Software (V 1.0.14029.14028).

[0391]

[0392] field

[0393] Bright field microscopy was used to detect iPSC morphology in the culture.

[0394] 1: Unsuccessful for bovine induced

[0395]

[0396] stem

[0397]

[0398] cells (i

[0399] Table 3 above describes the various cell types as well as various combinations and ratios of reprogramming factors examined and found unsuccessful. As an example, Figs 1A and IB show BDF cells that underwent electroporation with episomal vectors containing OCT4, SOX2 (Fig. 1A) or chimeric SOX2-17 (Fig. IB), KLF4, MYC and LIN28A, and failed to undergo reprogramming and produce iPSCs.

[0400] Example 2: Production of bovine induced pluripotent stem cells (iPSCs)

[0401] Episomal vectors containing the reprogramming factors hKLF4, bNANOG, hSALL4 and mPrdml4 were generated by subcloning the open reading frame of hKLF4, bNANOG, hSALL4 or mPrdml4 into pCXLE vector using EcoRI or Mfel enzymes, producing pCXLE-hKLF4, pCXLE-bNANOG, pCXLE-hSALL4 and pCXLE-mPRDM14. A novel chimeric SOX2 with transcriptional activator VP160 (GenScript) was also generated in an episomal vector, by introducing the VP 160 sequence into PCXLE-hSOX2 or PCXLE-hSOX2-hKLF4 with BstEII and Nsil, to produce pCXLE-hSOX2-VP160 and pCXLE-hSOX2-VP160-hKLF4. Episomal vectors pCXLE-hOCT4-shp53, pCXLE-hSOX2-17-hKLF4, and pCXWB-EBNAl were obtained from Addgene (Okita et al. 2011, Nat Methods, 8(5):409-12; Okita et al. 2012, Stem Cells., 31(3):458-66; MacCarthy et al. 2024, Cell Stem Cell., 4;31(1): 127-147).Angus fibroblast like cells (Aleph Farms) were cultured in Fibroblasts Medium-2 (FM-2) (ScienCell) - basal medium, 5% FBS, 1% fibroblast growth supplement-2, and 1% antibiotic solution (P / S) (ScienCell).

[0402] For electroporation, the cells were trypsinized and 5xl05cells were resuspended in 100 pL of R buffer (Life Technologies). Subsequently, the episomal plasmids pCXLE-hOCT4-shp53, pCXLE-hSOX2-VP160-hKLF4, pCXLE-hSALL4, pCXLE-bNANOG and pCXLE-mPRDM14 (lpg / 100, lpg / 100, 0.8pg / 100, 0.5pg / 100, 0.5pg / 100, respectively), together with 0.8pg / 100 pL of pCXWB-EBNAl episomal plasmid, were added to the cell suspension. Table 4 hereinabove summarizes the reprogramming factors / ratio used.

[0403] Electroporation was carried out with the NEON transfection system (Life Technologies; 1,650V, 10ms, 3 pulses) according to the manufacturer’s instructions.

[0404] To assess the efficiency of episomal vectors infections, flow cytometry was performed. Cells were washed with PBS, trypsinized and filtered through mesh paper. Flow cytometry analysis for GFP or tdTomato-positive cells was performed on a Beckman Coulter (Gallios) flow cytometer using the Kaluza Software (V1.0.14029.14028).

[0405] Subsequently, cells were seeded onto 6-well plates coated with mouse feeder cells, containing Fibroblasts Medium-2 (FM-2, ScienCell), consisting of 500mL of basal medium, 25mL of FBS (ScienCell), 5mL of fibroblast growth supplement-2 (ScienCell), and 5mL of antibiotic solution (P / S, ScienCell). The fibroblasts were cultured in FM-2 for 5 days, then the medium was exchanged to 50% FM-2 and 50% bESC medium (mTeSRl (STEMCELL) + 2.5pM IWR-1 (Focus Biomolecules) for 2 days, and then the medium was exchanged once again for 100% bESC medium for another 8 days. Following 8 days, plates were screened for bovine iPSC colonies, using bright field microscopy, then trypsinized and plated on a new mouse feeder-containing plate. biPSCs were passaged several times until stable proliferative biPSC colonies emerged.

[0406] First, the electroporation protocol was used on BDFs, to test their ability to produce bovine iPSCs. As shown in Fig 2A, electroporation of a combination of eight reprogramming factors, OCT4, chimeric SOX2-17, KLF4, LIN28A, MYC, NANOG, SALL4 and PRDM14 into BDF cells successfully generated iPSCs.

[0407] Said combination was then electroporated into fibroblast-like cells. Fig 2B showsthat the combination of the 8 reprogramming factors, OCT4, chimeric SOX2-17, KLF4, LIN28A, MYC, NANOG, SALL4 and PRDM14, can also produce bovine iPSCs in fibroblast-like cells. Fibroblast-like cells may be produced using the method disclosed in International (PCT) Patent Application Publication No. WO 2023 / 017509 to the Applicant of the present invention. As disclosed therein, the method enables massproduction of linage-committed progenitor cells that can be easily differentiated to various cells types including stromal cells.

[0408] Figs 3A-3B show the significance of the presence of the reprogramming factors OCT4, chimeric SOX2 and KLF4 in successfully generating iPCS in Angus-derived fibroblast like cells. Fig. 3A shows that a combination of the reprogramming factors OCT4, chimeric SOX2-VP160, KLF4, LIN28A, MYC, NANOG, SALL4 and PRDM14 generated iPSC in fibroblast-like cells. Fig 3B shows that the exclusion of either OCT4, chimeric SOX2 or KLF4 results in unsuccessful generation of iPSC. Figs 4A-4F show that, unexpectedly, a combination of only 5 reprogramming factors, OCT4, chimeric SOX2-17, KLF4, NANOG and SALL4 suffice to successfully generate iPSC in fibroblast-like cells. Fig 4A shows the iPSC generated by electroporation of the 5 reprogramming factors. Fig 4B shows the iPSC endogenous markers OCT4 and SOX2, indicating that this is indeed an iPSC, generated by introducing to a somatic cell the 5 reprogramming factors. Figs 4C-F show the iPSC endogenous markers bSOX2 (Fig.4C), bOCT4 (Fig. 4D), bNANOG (Fig. 4E) and bSALL4 (Fig. 4F) in fibroblast-like cells electroporated with the 5 reprogramming factors (5F iPSC pool) compared to untreated fibroblast-like cells (Fib-like cells), where no iPSC endogenous markers are expressed, in 3 independent replicates (1,2,3).

[0409] 3: Production of bovine induced

[0410]

[0411] stem cells (iPSCs) from bovine

[0412]

[0413] Episomal vectors containing the reprogramming factors hKLF4, bNANOG, hSALL4, mPrdml4, hc-MYC, hH-RAS and hTFAP2C were generated by subcloning the open reading frame of hKLF4, bNANOG, hSALL4, mPrdml4, hc-MYC, hH-RAS or hTFAP2C into pCXLE vector using EcoRI or Mfel enzymes, producing pCXLE-hKLF4, pCXLE-bNANOG, pCXLE-hSALL4, pCXLE-mPRDM14, pCXLE-hc-MYC, pCXLE-hH-RAS and pCXLE hTFAP2C. The novel chimeric SOX2 with transcriptional activatorVP 160 (GenScript) was generated as described in Example 2 herein above. Episomal vectors pCXLE-hOCT4-shp53, pCXLE-hSOX2-17-hKLF4, pCXLE hUL, and pCXWB-EBNA1 were obtained from Addgene (see Example 2 hereinabove). pCXLE p53DD-hJDP2 was synthesized by Twist Bioscience.

[0414] Bovine embryonic myoblasts (bEM) (Aleph Farms) and Angus fibroblast like cells (Aleph Farms) were cultured in DMEM (Gibco™, #11965092) containing 10% FBS (BI, #04-001-lA), 1% L-glutamine (Sigma, #G7513) and 1% penicillin- streptomycin (Sigma, #P4333).

[0415] For electroporation, the cells were trypsinized and 5xl05cells were resuspended in 100 pF of R buffer (Fife Technologies). Subsequently, the episomal plasmids pCXEE-hOCT4-shp53, pCXEE-hSOX2-17-hKEF4, pCXEE-hUE (hMYCF-EIN28A), pCXEE-bNANOG, pCXEE-hSAEE4, pCXEE-p53DD-hJDP2, pCXEE-hPRDM14 (0.7pg / 100, l.lpg / 100, 0.6pg / 100, 0.4pg / 100, 0.7pg / 100, 0.5pg / 100, 0.4pg / 100 respectively), together with 0.6pg / 100 pF of pCXWB-EBNAl episomal plasmid, were added to the cell suspension. Table 4 hereinabove summarizes the reprogramming factors / ratio used.

[0416] Electroporation was carried out with the NEON transfection system (Fife Technologies; 1,650V, 10ms, 3 pulses) according to the manufacturer’s instructions.

[0417] To assess the efficiency of episomal vectors infections, flow cytometry was performed. Cells were washed with PBS, trypsinized and filtered through mesh paper. Flow cytometry analysis for GFP or tdTomato-positive cells was performed on a Beckman Coulter (Gallios) flow cytometer using the Kaluza Software (V1.0.14029.14028).

[0418] Subsequently, cells were seeded onto 6-well plates coated with mouse feeder cells, containing DMEM (Gibco™, #11965092) containing 10% FBS (BI, #04-001-lA), 1% E-glutamine (Sigma, #G7513) and 1% penicillin- streptomycin (Sigma, #P4333). The myoblasts were cultured for 5 days, then the medium was exchanged to 50% DMEM containing 10% FBS as described above and 50% bESC medium (mTeSRl (STEMCEEE) + 2.5pM IWR-1 (Focus Biomolecules) for 2 days, and then the medium was exchanged once again for 100% bESC medium for another 8 days. Following 8 days, plates were screened for bovine iPSC colonies, using bright field microscopy, then trypsinized and plated on a new mouse feeder-containing plate. biPSCs were passaged several times until stable proliferative biPSC colonies emerged.As can be depicted from Figs 5A and 5B, the addition of the combination of OCT4, SOX2-17 (or SOX2-VP160), KLF4, LIN28A, MYCL, NANOG, SALL4 (7F) to bEM, together with any one of the following factors: PRDM14, H-RAS, c-MYC, TFAP2C and JDP2, was insufficient to induce inbred bEF somatic cell identity loss or initiate reprogramming. However, the introduction of p53DD, and to a larger extent, the combination of p53DD and JDP2 or p53DD, JDP2, and PRDM14 — successfully facilitated reprogramming, leading to the generation of stable and clearly defined iPSCs in bEM cells. JDP2 and p53DD have the nucleic acid sequence SEQ ID NO: 80 and 81, respectively.

[0419] Fig 5C demonstrates successful reprograming of both bEM and bEF to establish stable iPSCs after applying the 7F combination in addition to PRDM14, p53DD, and JDP2.

[0420] 4. Production of bovine induced

[0421]

[0422] stem cells (i

[0423]

[0424] from bovine

[0425]

[0426] The experiment was performed as described in Example 3 using the following factors: factors hOCT4, hSOX2-17, hKLF4, hLIN28A, hMYCL, p53DD and hJDP2. The results are presented in Fig. 6. As can be seen from the figure, bovine iPSCs were successfully prepared.

[0427] Example 5: Producing bovine iPSCs from bovine somatic cells bv viral infection and mRNA transfection of mesenchymal and non-mesenchymal cells

[0428] biPSC reprogramming via lentiviral or retroviral infections

[0429] For infection, replication-incompetent lentiviruses, as well as retroviruses containing the reprogramming factors OCT4, chimeric SOX2 [SOX2-17 / VP160], KLF4, NANOG, SALL4 and PRDM14 are obtained as above. Supernatant is collected 48 hours post-transfection, supplemented with polybrene, filtered, and used to infect cells, as above.

[0430] biPSC reprogramming via mRNA transfection

[0431] Bovine cells are seeded on Matrigel coated 6-well plates and transfected 4-6 times every 24 hours with OCT4, chimeric SOX2 [SOX2-17 / VP160], KLF4, NANOG, SALL4and PRDM14 mRNA. Cells are examined every day for morphology change and emergence of colonies.

[0432] Obtaining bovine iPSCs from bovine somatic cells is tested using the methods described hereinabove. Flow cytometry is used to assess the efficiency of lentiviral and episomal vectors infections. Bright field microscopy is used to detect iPSCs formation in the culture.

[0433] Typically, the expression of endogenous OCT4 and SOX2 is measured using specific antibodies; the expression of endogenous OCT4, SOX2, SALL4, and NANOG is examined using qPCR.

[0434] 6: Production of bovine induced

[0435]

[0436] stem cells (iPSCs) from bovine

[0437]

[0438] from obtained from inbred beef breed

[0439] The experiment is performed as described in Example 3 using the following combination of factors for generating iPSCs from somatic cells of an inbred beef breed: OCT4, chimeric SOX2 (SOX2-VP160 or SOX2-17), and KLF4 (or another factor of KLF family member), together with two of the following three factors: SAEE4 (or a family member), NANOG, and PRDM14 (or a family member), as well as JDP2 and p53DD, or p53DD alone.

[0440] The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and / or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention.

Claims

CLAIMS1. A method of producing one or more mammalian induced pluripotent stem cells (iPSCs) comprising introducing into one or more mammalian somatic cells a combination of five or more reprogramming factors or at least one exogenous polynucleotide encoding the five or more reprogramming factors, wherein the reprogramming factors comprise OCT4, chimeric SOX2, a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family, thereby producing one or more bovine iPSCs.

2. The method of claim 2, wherein said reprogramming factors comprise (i) OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, and a factor of the SALL family or (ii) OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, and a factor of the PRDM family.

3. The method of any one of the preceding claims, wherein said reprogramming factors comprise OCT4, a chimeric SOX2, a factor of the KLF family, NANOG, a factor of the SALL family, and a factor of the PRDM family.

4. The method of any one of the preceding claims, wherein the chimeric SOX2 comprises SOX2 or a truncated SOX2 and from 1 to 20 copies of an exogenous transactivation domain.

5. The method of claim 4, wherein the transactivation domain is derived from a protein selected from the group consisting VP16, VP48, VP64 and SOX17.

6. The method of claim 5, wherein the chimeric SOX2 comprises from 1 to 20 repeats of VP16 activation domains, preferably comprises 10 repeats of VP16 activation domains (VP 160).

7. The method of any one of the preceding claims, wherein the factor of the KLF family is selected from the group consisting of KLF4, KLF5, KLF2, KLF6 and KLF17.

8. The method of any one of the preceding claims, wherein the factor of the SALL family is selected from the group consisting of SALL4, SALL1, SALL2 and SALL3.

9. The method of any one of the preceding claims, wherein the factor of the PRDM family is selected from the group consisting of PRDM14 and PRDM1.

10. The method of any one of the preceding claims, wherein the reprogramming factors comprise OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, SALL4 and PRDM14.

11. The method of any one of the preceding claims, wherein the method further comprises introducing at least one additional reprograming factors selected from a factor of LIN28 family and a factor of MYC family or at least one exogenous polynucleotide encoding the at least one additional reprograming factor, preferably wherein the factor of LIN28 family is selected from LIN28A and LYN28B and a factor of MYC family is selected from MYC-L, MYC-N, and c-MYC.

12. The method of any one of the preceding claims, wherein said method further comprises introducing at least one agent downregulating a transcription factor selected from the group consisting of p53 and AP-1 or a part thereof, or the at least one exogenous polynucleotide encoding the at least one agent, preferably wherein an agent downregulating p53 is selected from p53DD, shp53 and GSE56 and the agent downregulating AP-1 or a part thereof is selected from JDP2, shFOS and shJUN.

13. The method of claim 12, wherein the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, SALL4, and p53DD.

14. The method of claim 12, wherein the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, SALL4, p53DD and JDP2.

15. The method of claim 12, wherein the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factors or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of thecombination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, SALL4, p53DD, JDP2 and PRDM14.

16. The method of claim 12, wherein the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, LIN28A, MYCL, NANOG, SALL4 and p53DD.

17. The method of claim 12, wherein the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, LIN28A, MYCL, SALL4, p53DD and JDP2.

18. The method of claim 12, wherein the method comprises introducing a combination comprising reprogramming factors and an agent downregulating a transcription factor or at least one exogenous polynucleotide encoding the reprogramming factors and the agent downregulating a transcription factor of the combination, wherein the combination comprises OCT4, a chimeric SOX2 selected from the group consisting of SOX2-17 and SOX2-VP160, KLF4, NANOG, SALL4, LIN28A, MYCL, p53DD, and PRDM14, and optionally JDP2.

19. A method of producing one or more mammalian induced pluripotent stem cells (iPSCs) comprising introducing into one or more mammalian somatic cells a combination comprising five or more reprogramming factors and one or more agents downregulating a transcription factor selected from the group consisting of p53, AP-1 or a part thereof, and a combination thereof, or at least one exogenous polynucleotide encoding the reprogramming factors and the one or more agents downregulating a transcription factor, wherein the reprogramming factors comprise OCT4, chimeric SOX2, a factor of the KLF family, a factor of LIN28 family and a factor of MYC family, thereby producing one ormore bovine iPSCs.

20. The method of claim 19, characterized by at least one of:(i) an agent downregulating p53 is selected from p53DD, shp53 and GSE56;(ii) an agent downregulating AP-1 or a part thereof is selected from JDP2, shFOS and shJUN;(iii) the chimeric SOX2 is selected from the group consisting of S 0X2- 17 and SOX2-VP160;(iv) the factor of the KLF family is selected from the group consisting of KLF4, KLF5, KLF2, KLF6 and KLF17;(v) the factor of the SALL family is selected from the group consisting of SALL4, SALL1, SALL2 and SALL3;(vi) the factor of LIN28 family is selected from LIN28A and LYN28B; and(vii) the factor of MYC family is selected from MYC-L, MYC-N, and c-MYC.

21. The method of any one of the preceding claims, wherein said method comprises introducing into the one or more mammalian somatic cells at least one exogenous polynucleotide encoding the reprogramming factors and optionally an agent downregulating a transcription factor.

22. The method of claim 21, wherein said method comprises introducing into the one or more mammalian somatic cells a plurality of polynucleotides, wherein each of the plurality of polynucleotides encodes the one or more reprogramming factors and / or the agent(s).

23. The method of claim 22, wherein each of the plurality of polynucleotides encodes a single reprogramming factor or agent.

24. The method of any one of the preceding claims, wherein the at least one polynucleotide is a gene-delivery and / or expression vector.

25. The method of claim 24, wherein the gene-delivery and / or expression vector is selected from the group consisting of an integrating vector and a non-integrating vector.

26. The method of claim 25, wherein the integrating vector is selected from the group consisting of lentiviral vector and retroviral vector and the non-integrating vector is selected from the group consisting of episomal vector, Sendai virus (SeV) vector, andadenovirus vector.

27. The method of any one of claims 21 to 26, wherein the at least one polynucleotide comprises a mRNA encoding the one or more reprogramming factors.

28. The method of any one of claims 1 to 20, wherein the method comprises introducing into one or more mammalian somatic cells the combination of reprogramming factor proteins and optionally one or more agent downregulating a transcription factor.

29. The method of any one of the preceding claims, wherein the reprogramming factors are mammalian factors.

30. The method of claim 29, wherein the mammalian reprogramming factors are selected from the group consisting of human reprogramming factors, ungulate reprogramming factors, murine reprogramming factors, and a combination thereof.

31. The method of claim 30, wherein the ungulate reprogramming factors are bovine.

32. The method of any one of the preceding claims, wherein the mammalian somatic cells are selected from peripheral blood cells, mesenchymal stem cells, fibroblasts, keratinocytes, urine-derived and epithelial cells.

33. The method of any one of the proceeding claims, wherein the mammalian somatic cells are bovine somatic cells.

34. The method of claim 33, wherein the bovine somatic cells are characterized by at least one of: (i) the somatic cells are fresh cell or cells obtained from a frozen stock, (ii) the bovine somatic cells are derived from an inbred animal or from an outbred animal, and (iii) the bovine somatic cells are selected from the group consisting of bovine fibroblasts and bovine fibroblasts-like cells.

35. The method of claim 34, wherein the bovine fibroblast cells are bovine dermal fibroblasts (BDF) and the fibroblast-like cells are mesenchymal cells differentiated from embryonic stem cells (ESCs) obtained from cattle.

36. The method of any one of the preceding claims, further comprising growing the produced iPSC cells.

37. A plurality of mammalian iPSCs produced by the method of any one of claims 138. The plurality of mammalian iPSCs of claim 37, wherein said iPSCs can propagate indefinitely in culture.

39. The plurality of the bovine iPSCs of claim 37 or 38, wherein said iPSCs express at least one endogenous factor selected from OCT4, SOX2, LIN28A, SALL4, UTF1, and ZFP42.

40. The of mammalian iPSCs of any one of claims 37 to 40, wherein the said iPSCs are bovine iPSCs.

41. The plurality of bovine iPSCs of claim 40, for use in producing cultured food product.

42. The plurality of iPSCs of claim 41, wherein the cultured food product is cultured meat.

43. A method for producing one or more mammalian somatic cells, the method comprising the steps of:(i) producing one or more mammalian iPSCs according to the method of any one of claims 1 to 36; and(ii) culturing the produced mammalian iPSCs under conditions enabling propagation and differentiation of the produced iPSC, thereby producing one or more mammalian somatic cells.

44. The method of claim 43, wherein culturing the produced bovine iPSCs of step (ii) is performed under a 2D or 3D culture conditions.

45. The method of any one of claims 43 to 44, wherein the mammalian cells are bovine cells.

46. The method of claim 45, wherein the one or more somatic cells are selected from the group consisting of stromal cells, skeletal muscle cells, adipocytes, endothelial cell, and any combination thereof.

47. Bovine somatic cells produced by the method of any one of claims 45 to 46, for use in producing a product selected from a cultured food product, a cosmetic product and a product for medical use.

48. The bovine somatic cells for the use of claim 47, wherein the product is a cultured food product being a cultured meat.

49. A chimeric SOX2-VP160 polypeptide comprising an amino acid sequence having at least 80% identity to the amino acid sequence set forth in SEQ ID NO: 1, for use in reprogramming bovine-derived somatic cell to produce bovine induced pluripotent stem cell (iPSC).

50. An induced pluripotent stem cell (iPSC), which is obtainable by introducing into a mammalian somatic cell at least one exogenous polynucleotide encoding five or more reprogramming factors, wherein the five reprogramming factors comprise OCT4, chimeric SOX2, and a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family.

51. A combination comprising five or more reprogramming factors or at least one polynucleotide encoding same, wherein the reprogramming factors comprise OCT4, chimeric SOX2, and a factor of the KLF family, and at least two reprogramming factors selected from the group consisting of NANOG, a factor of the SALL family and a factor of the PRDM family.

52. The combination of claim 51, wherein said combination further comprises one or more additional reprogramming factor or at least one additional polynucleotide encoding the one or more additional reprogramming factor, wherein the one or more additional reprograming factor is selected from the group consisting of LIN28A, MYCL, and a combination thereof.

53. The combination of any one of claims 51 to 52, wherein said combination further comprise at least one agent downregulating transcription factor selected from p53, AP-1 transcription factor or a part thereof, and a combination thereof.